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A b s t r a c t
Patients with severe symptomatic aortic stenosis have a poor prognosis with medical management alone, and surgical aortic 
valve replacement can improve symptoms and survival. In recent years, transcatheter aortic valve implantation (TAVI) has been 
demonstrated to improve survival in inoperable patients and to be an alternative treatment in patients in whom the risk of 
surgical morbidity or mortality is high or intermediate. A representative expert committee, summoned by the Association of 
Cardiovascular Interventions of the Polish Cardiac Society (ACVI) and the Polish Society of Cardio-Thoracic Surgeons, devel-
oped this Consensus Statement in transcatheter aortic valve implantation. It endorses the important role of a multi-disciplinary 
“TAVI team” in selecting patients for TAVI and defines operator and institutional requirements fundamental to the establish-
ment of a successful TAVI programme. The article summarises current evidence and provides specific recommendations on 
organisation and conduct of transcatheter treatment of patients with aortic valve disease in Poland.
Key words: clinical expert consensus document, aortic stenosis, aortic valve replacement, heart team, TAVI team, high-risk 
patients, percutaneous valve therapy, structural heart disease, transcatheter aortic valve implantation, transcatheter aortic 
valve replacement
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INTRODUCTION
Valvular heart disease is a major public health problem in 
developed countries. Aortic valve stenosis (AS) is its most 
common form, affecting more than 5% of the population 
aged > 65 years [1]. AS is a chronic disease, associated with 
poor prognosis when left untreated. Depending on the severity 
of symptoms, the mean survival of patients with a significant 
AS is two to five years [2]. Conservative treatment or balloon 
valvuloplasty do not prolong life in symptomatic patients. 
Surgical aortic valve replacement (SAVR) represents 
a well-documented standard of treatment of AS, performed ei-
ther with conventional or minimally invasive approaches. SAVR 
outcomes are favourable but depend on the patient’s age and 
the presence of concomitant diseases, factors defining the 
overall procedural risk as low, intermediate, high, very high, 
or prohibitive [3]. The prevalence of AS is predicted to rise 
along with the ageing population, leading to the enlargement 
of high- or prohibitive-risk groups of patients. Currently, 33% 
of them are estimated to be either disqualified from SAVR or 
not considered as potential candidates for such treatment [4]. 
With these patients in mind, a French cardiologist, 
Alain Cribier, implemented an endovascular treatment of 
aortic valve disease with the use of a stented bioprosthesis in 
2002. Since then, multiple registries and clinical trials have 
confirmed the safety and efficacy of transcatheter aortic 
valve implantation (TAVI, also transcatheter aortic valve re-
placement: TAVR). Its outcomes have improved with rapid 
technological advances and growing experience of operators, 
invasive cardiologists, and cardiac surgeons [5–8]. TAVI has 
become the treatment of choice in prohibitive-risk patients 
and the preferred approach to patients with high risk of 
conventional heart surgery, following the criteria set by the 
Joint European Society of Cardiology (ESC) and European 
Society of Cardio-Thoracic Surgeons (EACTS) Guidelines on 
the management of valvular heart disease [9].
The results of the latest clinical trials and growing experi-
ence of Polish cardiology and cardiac surgery centres point 
to beneficial outcomes in patients in whom the high risk 
of SAVR is a consequence of the porcelain aorta, previous 
coronary artery bypass grafting (CABG), prior chemotherapy 
or chest radiotherapy, osteoporosis, and other comorbidities 
[10]. In addition to AS, TAVI allows for an alternative treat-
ment of patients with significant aortic valve regurgitation as 
well as a dysfunctional, aortic or mitral, bioprosthesis [11]. 
The number of indications to TAVI in the high-risk patient 
group is steadily growing. Since the pioneering Alain Cribier’s 
procedure, TAVI has been performed in more than 200 thou-
sand patients worldwide. The first TAVI in Poland was con-
ducted using transapical access in Krakow on 25 November 
2008, followed by a transfemoral implantation in Zabrze on 
22 December 2008. In the years 2008–2016, 3058 TAVI 
procedures were performed in Poland, with 869 implants 
completed in 2016 (penetration rate: 22.6 TAVI/million 
population) [12].
Encouraging results of this novel therapy in prohibitive-, 
high-, and moderate-risk patients in Poland were possible 
thanks to the combination of several factors: full support 
and growing experience of national scientific societies, the 
introduction of dedicated TAVI programmes in centres with 
established invasive cardiology and cardiac surgery depart-
ments, as well as the organisation of integrated TAVI teams 
in each of them [13–22]. The role and indications to SAVR in 
the future will most probably reflect growing TAVI demand. 
Novel surgical bioprostheses are being introduced, with im-
proved anti-calcification solutions and technical innovations 
which facilitate rapid deployment in a setting of a minimally, 
sternum-sparring operation. Sutureless valves, which are 
similar to TAVI devices in their design, have been shown to 
offer excellent short and long-term durability, yet they remain 
underutilised due to reimbursement issues [23–26].
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A representative expert committee, summoned by the 
Association of Cardiovascular Interventions of the Polish Car-
diac Society (ACVI) and the Polish Society of Cardio-Thoracic 
Surgeons, developed this Consensus Statement in TAVI. The 
article summarises current evidence and provides specific 
recommendations on the organisation and conduct of tran-
scatheter treatment of patients with aortic valve disease in 
Poland. It does not replace the present or future ESC and 
EACTS guidelines and should be referred to in agreement 
with these publications. This document was fully approved 
by the Board of the Polish Cardiac Society and the Board of 
the Polish Society of Cardio-Thoracic Surgeons and National 
Consultants in Cardiology and Cardiac Surgery. 
DEFINITION OF TAVI/TAVR
A therapeutic procedure performed to normalise blood flow 
and its effective pressure gradient across the aortic valve in 
patients with acquired, significant aortic valve degeneration. 
The procedure also applies to diseases of mitral or tricuspid 
valves, as well as their degenerated bioprostheses, in high- 
or prohibitive-risk patients, in whom conventional surgery is 
prone to failure or an occurrence of serious complications. The 
decision on patient qualification to TAVI and the choice of 
access is made by a dedicated group of experts, the TAVI 
team, which includes a cardiologist and a cardiac surgeon 
experienced in TAVI procedures. 
TAVI OUTCOMES
The safety and efficacy of TAVI in patients with a symptomatic 
and significant aortic stenosis were assessed in registries and 
randomised multicentre clinical trials. Until now, they pro-
vided evidence for clinical utility of TAVI in patients with 
a prohibitive, high, and intermediate risk of conventional 
cardiac surgery.
TAVI in prohibitive-risk patients
The PARTNER 1 cohort B trial compared outcomes of conserva-
tive treatment with a transfemoral TAVI using a balloon-mount-
ed aortic valve bioprosthesis in symptomatic patients with 
a significant AS, who had been disqualified from conventional 
cardiac surgery based on the prohibitive risk of SAVR. The mean 
age of patients was 83 years. The mean Society of Thoracic 
Surgeons (STS) risk was 12.1 ± 6.1% in the conservative group 
vs. 11.2 ± 5.8% in the TAVI group, while the mean logistic 
EuroSCORE was 30.4 ± 19.1% vs. 26.4 ± 17.2%, respectively. 
Patients were refused surgery if the predicted 30-day risk of 
death or irreversible morbidity with surgery exceeded 50%. 
The mortality after one year was 50.7% with medical treat-
ment compared with 30.7% with TAVI (p < 0.001) [6]. At 
five-year follow-up, the mortality rates were 93.6% and 71.8%, 
respectively (p < 0.001). Five-year rates of cerebral stroke were 
comparable in both treatment groups (18.2% i 16.0%, p = 0.56) 
[27]. The study proved prohibitive-risk patients, who used to 
be qualified to medical treatment, achieved better short- and 
long-term survival with TAVI.
A non-randomised CoreValve US Pivotal Trial Extreme 
Risk Iliofemoral Study assessed TAVI using self-expanding 
bioprosthesis in non-operable patients. The mean age was 
83.2 years, STS risk score 10.3%. The one-year composite 
endpoint (all-cause mortality and cerebral stroke) occurred 
in 26% of patients, with 24.3% one-year mortality and 4.3% 
one-year stroke rates [28]. 
TAVI in high-risk patients
The randomised PARTNER 1 trial, cohort A, compared the 
effectiveness of SAVR with TAVI using balloon-mounted 
bioprosthesis implanted using a transfemoral or a transapi-
cal access, in symptomatic patients with severe AS and 
high risk of conventional cardiac surgery (defined as STS ≥ 10%). 
The mean population age was 84 years; the mean STS score 
was 11.7 ± 3.5% in the SAVR group and 11.8 ± 3.3% in the 
TAVI group. The mean logistic EuroSCORE was 29.2 ± 15.6% 
and 29.3 ± 16.5%, respectively. Analysis of one- and five-year 
mortality showed comparable outcomes in surgical and TAVI 
groups (26.8% and 24.2% vs. 62.4% and 67.8%, p < 0.76). 
Stroke rates were similar in both treatment groups in 
a five-year observation (11.3% and 10.4%, p = 0.61) [8, 29].
The CoreValve US Pivotal High-Risk Trial compared SAVR 
and TAVI using self-expandable bioprosthesis in patients 
with severe and symptomatic AS. All patients were high risk, 
defined as the estimated 30-day mortality ≥ 15%. The mean 
patient age was 83 years, STS 7.4%. One-year mortality was 
significantly higher in the surgical group than in TAVI (19.1% 
vs. 14.2%, p < 0.04), with a non-significant trend to a higher 
one-year stroke rate after surgery (12.6% vs. 8.8%, p = 0.1) [5]. 
Three-year mortality was comparable in both treatment 
groups (39.1% vs. 32.9%, p = 0.07), but the three-year 
stroke rate was significantly higher in the SAVR group (19.0% 
vs. 12.6%, p = 0.03) [30]. 
TAVI in intermediate risk patients
The PARTNER 2 randomised clinical trial compared SAVR with 
TAVI in intermediate-risk patients with symptomatic, severe AS 
(STS 4–8%). The mean age was 81 years, and STS was 5.8% 
in each group. The composite endpoint (all-cause mortality 
and stroke) did not differ between SAVR and TAVI [31]. In the 
transfemoral TAVI group, the risk of composite endpoint occur-
rence was significantly smaller in comparison to the SAVR group 
(HR = 0.79, p = 0.05, intention-to-treat) [7]. The SURTAVI 
randomised clinical trial compared SAVR with TAVI with the 
use of a self-expanding bioprosthesis. The mean age of patients 
was 79 years, and STS was 4.5%. At 24 months the estimated 
incidence of the primary endpoint (a composite of death from 
any cause or disabling stroke) was 14.0% in the SAVR group and 
12.6% in the TAVI group. Surgery was associated with higher 
rates of acute kidney injury, atrial fibrillation, and transfusion 
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requirements whereas TAVR had higher rates of residual aortic 
regurgitation and the need for pacemaker implantation [32]. 
Edwards Sapien 3 and Medtronic CoreValve EvolutR biopros-
theses have received a Conformité Européenne (CE) mark as 
well as acceptance of the America Food and Drug Administra-
tion (FDA) for the transcatheter treatment of intermediate-risk 
patients with severe aortic valve stenosis.
TAVI in low-risk patients
Reflecting the real-world expansion of TAVI procedures into 
low-risk patients, the cohort was assessed in clinical stud-
ies. In a pilot, randomised, clinical NOTION trial, SAVR was 
compared to TAVI in all-comers with symptomatic, severe AS. 
Their mean age was 79.1 years. 81.8% of patients were classi-
fied as low risk (STS < 4%). Two-year mortality and stroke rates 
were comparable in the two treatment arms (9.8% vs. 8.0%, 
p = 0.54 and 5.4% vs. 3.6%, p = 0.46, respectively) [33, 34]. 
With these results in mind, data of the prospective German 
GARY registry observed a comparable mortality in high-risk 
patients undergoing SAVR and TAVI, while a lower mortality 
was reported in SAVR vs. TAVI in low-risk patient groups [31].
Three large, randomised, clinical trials were initiated in 
2016 with the aim to compare SAVR with TAVI in low-risk 
patients with severe, symptomatic AS: PARTNER 3, using 
the Edwards Sapien 3 system (STS < 4%, age ≥ 65 years, 
NCT02675114), Medtronic Transcatheter Aortic Valve Re-
placement in Low-Risk Patients using the Medtronic EvolutR 
system (STS < 3%, no age limits, NCT02701283), and 
NOTION-2 using Symetis, Boston Lotus and St. Jude/Abbott 
Portico systems (all-comers, NCT02825134). Early results of 
these trials are expected to be announced in 2019.
TAVI in specific indications
Although mostly used in patients with significant aortic steno-
sis, transcatheter aortic valves have been successfully used to 
treat other forms of valvular diseases. Indeed, the first TAVI 
procedure was performed by a transseptal puncture, under 
local anaesthesia, in a patient with a regurgitant, bicuspid 
aortic valve (BAV). Due to increased risk of prosthesis mal-
position, residual paravalular leaks (PVL) or transprosthetic 
high gradient in challenging anatomy other than tricuspid 
aortic valve stenosis, patients with these indications were 
not included in randomised trials. Current evidence for 
TAVI in BAV, degenerated aortic bioprosthesis, pure native 
aortic regurgitation or low-flow, low-gradient aortic stenosis 
is based on registry data. Their summary presented below 
should guide TAVI teams in an individualised approach to 
such patients based on thorough assessment of procedural 
risk and the experience of operators.
Bicuspid aortic valve
In low-risk patients with a BAV and in those with concomitant 
aortopathy, surgical aortic valve replacement is the recom-
mended option for treatment [9, 35]. However, this most com-
mon congenital anomaly affects up to 2% of the population 
and almost uniquely requires SAVR during a patient lifetime. 
BAV has been a contraindication to TAVI in most clinical trials, 
as an asymmetrical BAV orifice may prevent full expansion 
of the implanted bioprosthesis. In addition, the stress of the 
calcified raphe on the valve frame is variable, leading to dif-
ficulty in appropriate device sizing. All these factors may give 
rise to the following complications.
 — PVL —  in low implantations (the device sealing is pro-
vided by the BAV orifice located up to 8 mm above the 
aortic annulus), in very eccentric BAV orifice and in case 
of unfavourable distribution of calcifications. PVL follow-
ing TAVI is a risk factor for earlier prosthesis degeneration, 
which is especially important in younger patients with 
BAV. High implantation and use of second-generation 
devices with sealing skirts or their repositionability allow 
reducing the rate of PVL.
 — Annulus rupture: observed mainly in balloon-expandable 
valves in the presence of bulky, asymmetric calcifica-
tions. Cautious use of undersized devices (in comparison 
to tricuspid aortic valve standards), use of balloon-sizing 
and self-expandable bioprostheses allow averting this 
dramatic adverse event.
 — Aortic dissection: The vulnerable ascending aorta of BAV 
patients may be prone to injury during TAVI catheter 
manipulation. Careful navigation and deflection of the 
TAVI system away from walls of the aortic arch and the 
ascending aorta during catheter passage is recommended 
in these high-risk patients.
 — Conduction abnormalities: an asymmetrical calcium 
distribution, with deposits located in the noncoronary 
cusp or valve oversizing, compared to an elliptical BAV 
orifice, increase the risk of new pacemaker implanta-
tion [36].
Current registry data provide guidance for the tran-
scatheter treatment of this challenging group of patients. The 
reported overall survival rate is similar in BAV and tricuspid 
aortic valve patients. Procedural complications seem to be 
more frequent in the BAV group, especially in patients receiv-
ing first-generation devices. In the largest registry published 
to-date, conversion to surgery was 2.5% vs. 0.3%, the need 
for a second valve implantation 7.2% vs. 2.2%, significant PVL 
15.9% vs. 10.3% and aortic root injury 4.5% vs. 0% in BAV 
and tricuspid aortic valve patients, respectively. It is important 
to note that these differences were not present in patients 
treated with second-generation devices [37]. 
In the light of encouraging study results supported by the 
outcomes of the Polish BAV registry, further multicentre stud-
ies are required before the expansion of TAVI to lower-risk 
patients with an increased proportion of BAV [38, 39]. They 
should analyse differences between device designs as well 
their long-term durability in the challenging BAV anatomy. In-
dependently, this group of patients requires careful evaluation 
of concomitant aortopathy in the decision-making process.
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Vale-in-Valve
The use of biologic prostheses for the treatment of aortic 
stenosis has increased steadily to over 50% in comparison to 
mechanical valves, obviating the need for lifelong coagula-
tion, but at the cost of the shorter durability of implanted 
bioprostheses. With increasing life expectancy of an ageing 
Polish population, the number of patients with surgical 
valve failure is expected to rise. Although reoperative 
surgical replacement is the current standard of care, the 
presence of comorbidities in elderly patients or technical 
difficulties after previous operations may impact the risk 
of reoperation [40].
The diversity of surgical aortic bioprosthesis requires 
knowledge of their design, methods of surgical implanta-
tion and specifically, the position of the suture ring in the 
aortic valve. We recommend considering the following 
Valve-in-Valve (ViV) aspects during patient screening to TAVI.
1. Type of bioprosthesis dysfunction:
 — stenosis: differentiation between valve stenosis and 
valve-size mismatch (especially in surgical valves 
size ≤ 21 mm);
 — regurgitation: differentiation between intravalvular 
and paravalvular regurgitation.
2. Valve sizing:
 — identification of the prosthesis true inner diameter. 
It is smaller than the labelled valve size or the inner 
stent diameter in stented valves, as valve tissue, its 
calcification or pannus ingrowth may narrow the true 
lumen. Transoesophageal echocardiography (TEE) 
and multislice computed tomography (MSCT) are 
indispensable tools in valve assessment. In addition, 
available medical software applications are helpful 
tools in TAVI guidance;
 — valve oversizing reduces the risk of embolisation and 
PVL at the expense of a higher gradient and earlier 
dysfunction of TAVI bioprosthesis.
3. Risk of coronary obstruction:
 — stentless valves, narrow sinuses of Valsalva and low 
coronary ostia are predictors of coronary obstruction 
by the leaflet of the prosthesis. Aortography during 
aortic balloon valvuloplasty may help to predict 
coronary artery closure [41];
 — in high risk of this complication, the use of retriev-
able devices and low implantation is recommended. 
Coronary artery wiring with coronary balloon place-
ment may also be beneficial, by allowing to deflect 
apposing tissues away from the occluded coronary 
ostium with subsequent stenting.
4. Balloon pre-dilatation is helpful only in select patients 
without fluoroscopic markers of the bioprosthesis, to 
detect the level of the reference plane and to assess the 
risk of coronary obstruction.
5. TAVI prosthesis positioning:
 — a sewing ring of the surgical valve prosthesis is 
the reference plane for TAVI. Its relationship with 
fluoroscopic markers is specific to the type of surgi-
cal prosthesis;
 — the target TAVI landing zone is located 4–5 mm 
below the sewing ring;
 — rapid ventricular pacing may help stabilise the TAVI 
system during implantation and reduce the amount 
of contrast used.
Based on published ViV registry data, most frequent 
complications were: valve embolisation (12.4%), pacemaker 
implantation (7.6%; lower than observed in native TAVI), 
coronary obstruction (2.2%) and stroke (1.4%). The mean 
transvalvular gradient after ViV was 15.5 mm Hg, higher than 
in native TAVI reports of < 10 mm Hg. The mean mortality 
rate at one year was 15.1%. Factors associated with increased 
mortality were smaller surgical valves, stenotic dysfunction 
and transapical approach [42].
Currently available TAVI systems may be used for ViV in 
the mitral position to treat patients with degenerated mitral 
bioprostheses or recurrent regurgitation after a complete-ring 
annuloplasty. Such procedures may be performed transapi-
cally or transseptally, depending on patient anatomy, the 
TAVI prosthesis used and operators’experience. Careful 
pre-procedural planning with data on previous mitral opera-
tion, TEE and MSCT analysis are crucial to assess ViV feasibility, 
to select the optimal type and size of TAVI bioprosthesis and 
to agree on its intraprocedural positioning and the degree of 
over-expansion [43].
Native aortic valve regurgitation
Native aortic valve regurgitation (NAVR) constitutes 10.9% of 
all native valve disease. The most common causes of NAVR 
are congenital valve malformations, including BAV, followed 
by acquired diseases such as infective endocarditis, rheumatic 
heart disease, vasculitis, radiotherapy, chest trauma or left 
ventricular assist device valve injury. The clinical course may 
be acute or chronic, leading to the development of congestive 
heart failure and pulmonary hypertension, owing to volume 
overload and left ventricular dysfunction [4].
Transcatheter treatment of NAVR is challenged by several 
clinical and anatomic factors. Patients presenting with aortic 
regurgitation are usually younger than patients with AS, due 
to the different pathophysiology of valve degeneration. Ac-
tive endocarditis, annuloectasia or aortic dissection may be 
prohibitive for TAVI. Quick NAVR progression to left and 
right ventricular failure render patients more complex and 
vulnerable to treat than in case of degenerative AS. Absence 
of valvular calcification complicates the anchoring of a bio-
prosthesis in the aortic annulus, with an increased risk of valve 
embolisation or PVL. The dilatation of the left ventricle due to 
volume overload may increase the size of the annulus, exceed-
ing the range of currently available prostheses. The increased 
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stroke volume and regurgitant jet limit device control during 
its positioning and implantation.
The choice of bioprosthesis and its sizing requires thor-
ough TEE and MSCT assessment, although the quality of 
computed tomography may be lowered by accompanying 
tachycardia. The choice of recapturable self-positioning TAVI 
systems with feelers, clippers and other fixation mechanism, 
may be preferred. We advise a patient-specific prosthesis over-
sizing to provide increased radial force in this native anatomy, 
careful observation of the bioprosthesis waist during implanta-
tion and, in specific cases, the performance of a tug test before 
the release of a self-expandable prosthesis. Such approach 
may prevent valve malpositioning, migration or significant 
paravalvular regurgitation at the expense of increased risk of 
annulus rupture or valve malposition. Balloon-expandable 
prostheses have been considered unsuitable for NAVR due 
to lack of calcification to anchor the prosthesis, yet recent 
publication of their use with adequate oversizing suggest its 
safety in highly selected patients [44]. Results of a limited 
number of heterogenous studies show that TAVI is techni-
cally feasible in selected high-risk patients with native pure 
aortic regurgitation, with acceptable 30-day mortality (8%, CI 
4–12%). The occurrence of a second valve implantation and 
the rate of residual moderate or severe aortic regurgitation 
were 7% and 9%, respectively [11, 45].
Low-flow low-gradient aortic stenosis  
with normal ejection fraction
In symptomatic patients with severe AS (aortic valve area 
[AVA] < 1 cm2 or index AVA < 0.6 cm2/m2) and low peak 
aortic velocity (< 4 m/s) or low mean Doppler gradient 
(< 40 mm Hg), the discordance may reflect a low stroke vol-
ume index, despite a normal left ventricular ejection fraction 
(paradoxical low-flow low gradient aortic stenosis [PLF-LGAS]). 
Such phenomenon has been associated with the presence 
of small ventricular cavities, severe concentric hypertrophy, 
increased afterload, restrictive physiology, systolic dysfunc-
tion and myocardial fibrosis [9, 46]. Importantly, this group 
has a higher prevalence of comorbidities, including atrial 
fibrillation and arterial hypertension, which requires careful 
differentiation of symptoms and their correlation with results 
of diagnostic studies:
 — a critical review of echocardiography measurements is 
necessary, with confirmation of the left ventricular out-
flow tract diameter (TEE or cardiac magnetic resonance), 
visualisation of leaflet calcification and reduction of their 
opening, analysis of peak flow velocity, the presence of 
left ventricular hypertrophy and global strain, not attribut-
able to other diseases;
 — MSCT-based aortic valve calcium scoring may support 
the diagnosis;
 — measurement of the natriuretic peptide may confirm the 
presence of heart failure. 
So far studies have reported disparate results regarding 
the significance and prognosis of this condition. Initial reports 
showed a poorer prognosis in comparison to patients with high 
gradient AS, while a recent study has provided evidence for 
comparable outcomes of PLF-LGAS to that of patients with 
a moderate AS [47].
Paradoxical low-flow low gradient aortic stenosis was 
observed in 20.8% of patients treated with TAVI or SAVR in 
the GARY registry. Reported TAVI outcomes and complica-
tion rates were comparable with high gradient AS patients, 
and significantly better than in low gradient AS and reduced 
left ventricular function (one-year mortality 22.3% vs. 32.3%, 
respectively) [48].
Further research is needed to better understand the 
natural history and impact of SAVR and TAVI in PLF-LGAS. 
Currently, treatment with SAVR or TAVI should be reserved by 
the Heart Team for selected symptomatic patients, in whom 
additional diagnostic studies support the diagnosis.
The durability of transcatheter  
and surgical aortic bioprostheses 
Any treatment of aortic valve disease should offer a high 
profile of safety and a permanent outcome. The introduction 
of TAVI began in prohibitive and high-risk patients, whose 
projected survival is significantly shorter than in intermediate 
or low-risk patients. Along with the improvement of access 
to TAVI technology and its spread towards lower-risk groups, 
maintaining the durability of implanted biological prostheses 
is of particular importance. 
Prosthetic dysfunction may present in the form of its 
stenosis or insufficiency. Their criteria have been defined 
by the Valve Academic Research Consortium 2 (VARC-2): 
a mean pressure gradient > 20 mm Hg, effective orifice 
area < 1.1 cm2, Doppler Velocity Index < 0.35 or effective 
regurgitant orifice area > 0.1 cm2, presuming an optimal and 
stable 30-day result of implantation [49]. The long-term sig-
nificance of a MSCT-derived leaflet calcification or reduced 
motion in a TAVI bioprosthesis, without accompanying 
stenosis or regurgitation, is yet unknown [50]. 
Based on more than 10 years of observation of surgical 
patients, the following risk factors for premature degeneration 
of biological aortic valve prostheses have been recognised: 
 — patient age, male sex, renal failure, chronic inflammatory 
diseases, immunosuppression; 
 — endocarditis, thrombosis;
 — procedural factors: PVL, annulus-prosthesis mismatch, 
elliptical shape of the implanted prosthesis [51].
Due to construction similarities, the above factors may 
also be valid for TAVI systems. The degree of the frame and 
leaflet folding, the duration of crimping, and the number of 
system recaptures and post-dilatations may further impact 
TAVI durability. Based on available registry data, the most com-
mon factors responsible for early transcatheter degeneration 
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are endocarditis, thrombosis, leaflet calcification, late pros-
thesis migration, and valve distortion during chest compres-
sion (in balloon expandable valves) [52]. The recommended 
imaging follow-up in patients after TAVI and the management 
of suspected valve thrombosis are described further in the 
“Post-procedural management” chapter. 
In a five-year follow-up of inoperable patients included in the 
PARTNER 1 trial, the area of transcatheter aortic valves and their 
mean aortic pressure gradient were intact (1.52 ± 0.28 cm2 and 
10.6 ± 3.9 mm Hg) [27]. Furthermore, in a five-year observation 
of high-risk patients of the PARTNER 1 trial treated surgically or 
with TAVI the valve area and the mean aortic pressure gradient 
were constant since the time of implantation and comparable be-
tween treatment groups (1.5 vs. 1.6 cm2, p = 0.29, 10.6 mm Hg 
vs. 10.7 mm Hg, p = 0.92, respectively) [29]. Similarly, 
the CoreValve US Pivotal High-Risk Study observed stable 
echocardiographic parameters of implanted bioprostheses 
in a three-year follow-up of high-risk patients, but the results 
were significantly worse in the surgical group in comparison to 
TAVI (1.53 cm2 vs. 1.79 cm2, p < 0.001 and 11.4 mm Hg vs. 
7.62 mm Hg, p < 0.001) [30]. In the SURTAVI study assessing 
moderate-risk patients, the TAVI group had lower mean aor-
tic-valve gradients and larger aortic-valve areas than did the SAVR 
group. However, moderate or severe residual paravalvular regur-
gitation was more common in the TAVI group at one year (15.3% 
vs. 0.6%, respectively) [32]. Likewise, in a one-year observation of 
a low-risk patient population included in the NOTION trial, the 
effective TAVI prosthesis area and the mean aortic pressure gradi-
ent remained intact. Echocardiographic parameters were signifi-
cantly worse in the surgical group in comparison to the TAVI group 
(1.3 cm2 vs. 1.6 cm2, p < 0.001 and 13.0 mm Hg vs. 9.0 mm Hg, 
p < 0.001, respectively) [34]. 
An international registry assessing long-term durability 
of transcatheter aortic valves (VAlve Long-term durability 
International Data [VALID]) includes the first-generation TAVI 
systems implanted since 2002. Its results are still pending 
publication. Expansion of TAVI indications to younger, low- 
and moderate-risk patients, will depend on evidence of 
favourable, ≥ 10-year outcomes for this treatment modality. 
RISK ASSESSMENT AND TREATMENT  
OF AORTIC VALVE DISEASES
Risk of a classic cardiac surgical procedure
Deciding on the treatment of aortic valve disease requires 
assessment of surgical risk associated with the planned 
procedure. Both ESC and EACS guidelines, along with state-
ments of American scientific societies, recommend using the 
following risk score calculators in patients with valvular heart 
diseases: STS score and EuroSCORE II. They are available 
online at http://riskcalc.sts.org/ and http://www.euroscore.
org/, respectively. 
Based on results obtained, patients are stratified into four 
groups of surgical risk:
 — low — STS < 4%, EuroSCORE II < 4%;
 — intermediate: STS 4–8%, EuroSCORE II 4–8%;
 — high: STS ≥ 8%, EuroSCORE II ≥ 8% (or Log Euro-
SCORE ≥ 20%);
 — prohibitive (non-operable): a calculated 30-day risk of 
mortality and morbidity exceeding 50% [9, 53, 54]. 
The previously-mentioned randomised clinical trials pro-
vided evidence for TAVI safety and efficacy in patients with 
prohibitive, high, and intermediate risk of SAVR.
Current risk calculators do not include all factors affecting 
outcomes of cardiac surgery and influencing the decision on 
the transcatheter treatment of the heart valve disease [55]. 
Therefore, we recommend inclusion of the following factors 
or comorbidities: 
 — heavy calcium burden of the ascending aorta (a porce-
lain aorta);
 — prior chest radiotherapy;
 — chest deformations;
 — liver diseases;
 — osteoporosis;
 — patent CABG or their track across the line of the sternum;
 — neoplasm;
 — frailty.
Currently used risk scales are based on cohorts of pa-
tients who underwent SAVR, and they are not specific for 
rapidly evolving TAVI procedures. Cardiology and cardiac 
surgery societies should work jointly in the future to provide 
an accurate definition of risk groups of patients qualified 
to TAVI. 
Patient screening and qualification to TAVI
The complex examination of a patient referred for TAVI can 
be performed in a referring hospital or a TAVI centre (Fig. 1). 
Local protocols for patient screening should include [22]: 
 — clinical data allowing for the STS and/or EuroSCORE 
risk assessment;
 — valid information not covered by contemporary surgical 
risk scales;
 — data on comorbidities and medical history, their course, 
and potential impact on proposed treatment;
 — complete diagnostics of comorbidities, such as coronary 
artery disease, chronic pulmonary obstructive disease, 
cancer, and renal failure;
 — assessment of cognitive and mental disorders;
 — echocardiographic evaluation of:
• morphology and function of the aortic valve;
• morphology and function of other heart valves;
• other structural heart diseases and/or defects;
• myocardial function;
• pulmonary artery pressure;
 — ultrasound examination of carotid arteries;
 — diagnosis of coronary artery disease: invasive or MSCT 
coronary angiography;
 — the MSCT of the heart and peripheral vessels;
 — in the presence of contraindications to the MSCT:
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• magnetic resonance of heart and peripheral arteries;
• three-dimensional (3D) echocardiography;
• peripheral artery angiography or a vascular ultra-
sound examination.
Echocardiography
Transthoracic and transoesophageal echocardiography, 
optimally three-dimensional (3D-TTE and 3D-TEE), allow 
for an accurate analysis of the aortic valve morphology. 
3D-TEE-derived parameters reproduce results obtained from 
the heart MSCT. TEE remains a valuable tool in periprocedural 
monitoring, supporting decision-making on valve sizing, bal-
loon valvuloplasty, and assessment of PVL [56, 57].
Multislice computed tomography
MSCT is pivotal in patient screening for TAVI and should be 
performed unless evident contraindications are present. Ex-
amination of peripheral arteries allows a decision to be made 
regarding the optimal access route. It should include assess-
ment of the depth of subcutaneous tissue overlying the artery, 
diameters, tortuosity, and pattern of calcifications of femoral, 
iliac, and subclavian arteries and evaluation of the aortic arch 
morphology. The following MSCT-derived parameters allow 
us to choose the proper size of bioprosthesis: aortic valve 
perimeter and area, left ventricular outflow tract diameter, 
coronary sinus diameter, sino-tubular junction height and 
diameter (STJ), as well as distances of coronary artery ostia 
from the plane of the virtual aortic valve annulus.
MSCT allows determination of the optimal C-arm pro-
jection during TAVI procedure, significantly reducing the 
total amount of contrast needed for valve implantation. The 
MSCT-based analysis of the amount and spatial distribution of 
aortic annulus and leaflet calcification may limit the frequency 
of post-implantation PVL in TAVI [58]. 
We propose the following two-stage computed tomo-
graphy protocol [19]:
1. Contrast MSCT:
 — range: from carotid arteries to the cardiac apex;
 — electrocardiogram (ECG)-gating: retrospective (op-
timal) or prospective;
 — slice thickness: < 1 mm.
2. Contrast MSCT angiography: from the thoracic aorta 
to lower limb arteries (unless the transapical route has 
already been chosen):
 — if scanning in one setting, allow a 15-s delay between 
cardiac and abdominal phases (to allow the patient 
to breathe and ECG gating to turn off);
 — range: base of the heart and down to the lesser tro-
chanter, including the abdominal aorta to common 
femoral arteries;
 — non-ECG gated;
 — slice thickness: < 1 mm.
3. Intravenous contrast injection protocols: depending 
on the computed tomography hardware and injection 
systems, they should be adjusted to the patient body 
composition and the renal function. Variable injec-
tion rates during the MSCT acquisition allow a sub-
stantial reduction of the amount of injected contrast 
medium [59]. 
MSCT allows quantification of aortic valve calcification, 
which is a risk factor for the progression of the aortic stenosis, 
future cardiovascular adverse events, and the need for a pace-
maker implantation after TAVI. The amount of calcium in the 
TAVI device landing zone, defined as a volume or Agatston 
units, is a predictor of residual PVL [60, 61].
Functional assessment of the aortic valve
Assessment of the severity of the aortic valve disease should 
be based on the echocardiography, using ESC guidelines 
criteria [9]. In patients with a suspected low-grade aortic 
stenosis, a dobutamine stress test echocardiography is 
recommended to help define both the nature and severity 
of the disease, and in relation to the left ventricular con-
tractile reserve.
Figure 1. Patient diagnosis and screening for transcatheter aortic valve implantation (TAVI); 6MWT — 6-minute walk test;  
SAVR — surgical aortic valve replacement; STS — Society of Thoracic Surgeons; Katz ADL — Katz Index of Independence in  
Activities of Daily Living; MSCT — multislice computed tomography
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Morphological assessment of the aortic valve 
A precise analysis of the aortic valve anatomy is crucial in a pa-
tient qualification pathway to TAVI. MSCT is a gold-standard 
examination used for the recognition of the aortic valve ap-
paratus and an anatomical relationship between the aortic 
valve and its surrounding structures. In cases of uncertain or 
unreliable MSCT results, they should be verified by TEE [38]. 
Assessment of coronary anatomy  
and coronary revascularisation
Coronary angiography is recommended in patients qualified 
to SAVR (I C class of recommendations) [9]. The knowledge 
of coronary artery anatomy is essential and allows for addi-
tional risk and clinical/procedural stratification. Aortic valve 
replacement combined with CABG improves prognosis in 
patients with a significant coronary artery disease and may 
be reconsidered in cases of coexisting multivessel coronary 
disease [62, 63]. Although coronary artery disease is present in 
34–75% of patients qualified to TAVI, its impact on long-term 
mortality has not been proven [5, 6, 8, 64, 65]. Also, available 
registry data do not demonstrate short- and long-term benefit 
of percutaneous coronary intervention (PCI) performed before 
TAVI [66–70]. These observations may result from variable 
criteria used for the definition of significant coronary lesions 
and problems with accurate assessment of fractional flow 
reserve and the instantaneous wave-free ratio in patients with 
a significant aortic valve disease [71]. 
While waiting for more evidence gathered from clinical 
trials and with further widening of TAVI indications to popu-
lations with longer life expectancy, we recommend taking 
the decision on revascularisation in TAVI Teams, following 
ESC/EACTS guidelines for the management of valvular heart 
diseases and myocardial revascularisation. In current clinical 
practice, angiographically significant stenosis of proximal 
segments of main coronary arteries, including the left main, 
depending on a SYNTAX Score II, are treated either with 
coronary angioplasty or bypass grafting after considering the 
procedural risk [72]. Ostial coronary lesions require careful 
stent positioning to avoid its future collision with the implanted 
aortic valve bioprosthesis. It is of particular importance in 
patients with a narrow anatomy of coronary sinuses. It should 
be noted that conditions of PCI after TAVI depend on the type 
of implanted bioprosthesis and its position relative to ostia of 
coronary arteries. In patients with advanced coronary artery 
disease and a high estimated risk of their percutaneous treat-
ment or after its failed attempt, we recommend considering 
a repeat consultation towards the surgical treatment: SAVR 
combined with CABG. In patients with a clinically dominant 
importance of aortic stenosis, revascularisation should not 
postpone TAVI treatment [72]. The proposed treatment 
algorithm in patients with coronary artery disease, who are 
qualified to TAVI, is presented in Figure 2. 
Assessment of vascular access
A thorough access site assessment is an indispensable part of 
the patient screening pathway to TAVI. The imaging should 
range from all available TAVI access sites to the site of valve 
implantation. MSCT allows analysis of all currently used TAVI 
routes, with an accurate definition of vessel diameters, their 
tortuosity, and patterns of their calcification. Angiography 
remains inferior in this context while using comparable 
amounts of contrast agents. In patients with advanced renal 
Figure 2. Recommended procedure in patients with diagnosed coronary artery disease, qualified to transcatheter aortic valve 
implantation (TAVI) by the TAVI team; AVR — aortic valve replacement; CABG — coronary artery bypass grafting; PCI — percuta-
neous coronary intervention
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failure, with a high risk of contrast nephropathy, magnetic 
resonance imaging or, to a lesser extent, vascular ultrasound 
permit competent analysis of vascular access in TAVI. 
Currently, the following access sites are used for TAVI pro-
cedures:
4. Transvascular:
 — transfemoral: allowing an entirely percutaneous 
valve implantation with the subsequent vascular 
closure of the puncture site;
 — trans-subclavian;
 — transaxillary;
 — transcarotid;
 — transcaval, caval-aortic.
5. Transthoracic:
 — transapical: using a left lateral mini-thoracotomy;
 — transaortic: using a mini-sternotomy or a right lateral 
mini-thoracotomy.
The common femoral artery is the preferred and most 
frequently used vascular access site. Published data has proven 
the presence of the most favourable TAVI outcomes using 
transfemoral approach. Therefore, the femoral artery is the 
first-choice access, and its evaluation should be performed 
in all patients referred to TAVI [7, 73]. Outer diameters of 
currently used transfemoral TAVI systems do not exceed 
8 mm. With the most advanced technology the procedure 
is possible via femoral arteries with diameters ≥ 5 mm, 
using percutaneous closure devices or a surgical arterial 
cut-down, the latter performed after 2–3 cm incision of 
the overlying skin. Currently, the artery preclosure and 
the surgical access are equally safe and efficient [74, 75]. 
Their choice should depend on the experience and pref-
erences of the TAVI centre, considering its outcomes and 
complication rates [76].
Transfemoral access should be preferred in all TAVI 
patients. In the case of a very small artery diameter ≤ 5 mm 
or the presence of extensive atherosclerosis or calcifications, 
significantly narrowing the vessel lumen, the TAVI team should 
consider an alternative vascular approach. If no contraindica-
tions to general anaesthesia exist, a transthoracic access should 
be considered [77, 78].
The transapical implantation is performed under general 
anaesthesia. After minimally-invasive skin cut-down in the 
fifth or sixth left intercostal space, the apex is visualised and 
prepared for puncture and guidewire insertion across the 
aortic valve to the descending aorta. One of the major benefits 
of the transapical approach is a small distance between the 
apex and aortic valve, allowing for a stable and controlled 
valve deployment. However, due to more invasive nature, 
the transapical approach remains a secondary alternative. 
Functional patient assessment
The assessment of physical activity, cognitive function, and 
nutrition is increasingly used to identify patients with a pos-
sibly futile outcome of proposed SAVR or TAVI. 
1. Any decrease in the six-point scale Katz Index of Inde-
pendence in Activities of Daily Living (Katz ADL) leads 
to an increased risk of procedural complications and 
a worse long-term outcome in patients undergoing 
TAVI [79]. 
2. Similarly, a reduced exercise capacity indicated by the 
6-m walking test (6MWT) distance under 150 m or a 5-m 
walking test duration exceeding 6 s are predictive of poor 
outcomes after TAVI [80–82]. 
3. AHA/ACC guidelines on managing patients with valvular 
heart diseases advocate frailty assessment in addition to 
global risk scores when assessing procedural risk: the pres-
ence of at least two frailty indexes indicates an increased 
risk of the planned procedure [53].
4. The Mini-Mental Status examination allows detection 
of disturbances of the cognitive function or dementia. 
5. The visual assessment of the patient stature and nutrition, 
paired with the body mass index, are valuable tools in 
routine patient assessment before aortic valve replace-
ment and TAVI, allowing prediction of worse procedural 
and long-term outcome. 
The presented scales and indices should be complemen-
tary to the general evaluation of the patient referred to TAVI. 
Quality of life assessment
Treatment of valvular diseases in elderly patients with multiple 
comorbidities may not extend their long-term survival but 
may improve their quality of life (QoL). The recommended 
QoL scales used in TAVI patients are the heart-failure specific 
Kansas City Cardiomyopathy Questionnaire (KCCQ) and 
a general EuroQoL 5-Dimensions 5-Levels Questionnaire 
(EQ-5D-5L). The observation of QoL changes before and 
after the intervention allows assessment of the clinical benefit 
from the treatment. In turn, such analysis will allow a better 
description and selection of patients with the greatest potential 
QoL increase after TAVI [83, 84].
Patients unlikely to benefit from TAVI
Despite the growing experience of TAVI centres, advances 
in technology, and reduction of procedural complications, 
certain patients receive no benefit from the TAVI treat-
ment regarding their clinical status, QoL, and survival. The 
PARTNER, FRANCE 2, and TARIS clinical trials identified 
factors associated with a futile post-TAVI outcome. They are 
presented in Table 1 [85–89]. In patients with risk factors 
for poor outcomes after TAVI, the TAVI team should inform 
the patient and the family about the higher probability of 
procedural complications and possible suboptimal long-term 
outcome of TAVI.
Recommendations for treatment of patients  
with significant aortic valve stenosis
1. The decision on the optimal treatment of patients with 
a severe, symptomatic aortic valve disease should be 
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made by a multidisciplinary TAVI team experienced in 
patient screening and management during TAVI proce-
dures. It should include at least: two certified TAVI opera-
tors (an interventional cardiologist and a cardiac surgeon), 
an echocardiographer, and an anaesthesiologist [22, 90].
2. Prohibitive-risk patients should be qualified to TAVI first 
[6, 28, 91].
3. High-risk patients (STS ≥ 8%, EuroSCORE II ≥ 8%, log 
EuroSCORE ≥ 20%) should be qualified to TAVI first 
[5, 8, 9, 53].
4. The decision on the treatment strategy of the following 
groups of patients should depend on the TAVI team:
 — intermediate-risk patients [5, 7–9, 32, 35, 53];
 — patients aged ≥ 85 [5, 8, 9, 53];
 — patients with a degenerated aortic valve bioprosthe-
sis or with a history of previous cardiac operations 
unamenable to SAVR [42, 92–94];
 — patients with the following risks of cardiac surgery:
• extensive calcification of the ascending aorta 
(porcelain aorta);
• history of chest radiotherapy;
• chest deformations;
• liver failure;
• osteoporosis;
• active or recent history of cancer;
• frailty syndrome.
5. Low-risk patients < 75-year-old (STS < 4%, EuroSCORE II 
< 4%, log EuroSCORE < 10%) should be first referred to 
the surgical aortic valve replacement [9, 95].
6. In unstable patients with severe aortic stenosis and with 
high operative risk or awaiting a non-cardiac operation, 
aortic balloon valvuloplasty should be considered alone, 
or as a bridge to SAVR or TAVI therapy. 
7. In unstable patients already qualified to TAVI, aortic bal-
loon valvuloplasty should be considered as a bridge to 
a planned TAVI procedure. 
8. Aortic balloon valvuloplasty can also be considered as a pal-
liative treatment in patients with multiple risk factors render-
ing cardiac surgery risk prohibitive and TAVI impossible.
9. Patients with a predicted poor outcome, including 
< one-year survival, should be qualified to a palliative 
treatment (conservative or aortic balloon valvuloplasty).
TAVI PROGRAMME
TAVI team
Transcatheter aortic valve implantation was introduced as an 
alternative treatment to the standard cardiac surgery operation 
in patients with high-risk of SAVR complications. The process of 
decision-making in this group of patients in highly complex and 
requires proper judgement in wide areas of medicine: interven-
tional cardiology, cardiac surgery, echocardiography, radiology, 
anaesthesiology, and vascular surgery. The support of other 
specialists is often required; neurologists, gastroenterologists, 
geriatricians, pulmonologists, nephrologists, and oncologists may 
participate in patient qualification to optimal therapy. Based on 
this experience, setup of the TAVI team is essential and obligatory 
in every TAVI centre [13–15, 17–19, 22, 90, 95–100]. 
The TAVI team is a multidisciplinary group of specialists 
overviewing and responsible for the TAVI programme in their 
centre. Its task is to combine the knowledge of diagnosis, 
treatment decisions, postoperative care, and rehabilita-
tion in patients with structural heart diseases. Independ-
ent TAVI operators — an interventional cardiologist and 
a cardiac surgeon, all certified by corresponding scientific 
societies (ACVI and the Polish Society of Cardio-Thoracic 
Surgeons) — constitute the core part of the team. The 
group also includes other specialists with skills, experience, 
and knowledge required to assess patients referred to TAVI 
objectively. They should be able to decide on the efficient 
and safe therapy of valvular heart diseases. Also, they 
should be qualified in the treatment of aortic valve diseases 
and aortic aneurysm, ensuring high-quality postoperative 
care. Appointment of such teams, who plan and perform 
structural heart interventions, significantly improves the 
outcome of such complex therapy.
The TAVI team includes:
 — operators: interventional cardiologists and cardiac sur-
geons, all certified in TAVI;
 — specialists qualified in the imaging of the cardiovascular 
system (cardiologists experienced in the non-invasive 
cardiovascular imaging, radiologist);
 — nurses engaged in the care of patients qualified to TAVI;
 — a cardiologist;
 — an anaesthesiologist.
Table 1. Clinical factors predicting poor outcomes after  
transcatheter aortic valve implantation
Diseases Factors
Chronic lung diseases 6-minute walk test (6MWT) < 150 m
Oxygen therapy
Advanced renal failure Atrial fibrillation
Renal dialysis
Frailty Katz ADL < 6
6-minute walk test < 150 m
Cardiovascular diseases LVEF < 30%
Pulmonary hypertension  
(mean PAP > 25 mm Hg)
Low-gradient aortic valve stenosis
Low cardiac output (< 35 mL/m2)
Severe degenerative mitral valve 
regurgitation
Katz ADL — Katz Index of Independence in Activities of Daily Living; 
LVEF — left ventricular ejection fraction; PAP — pulmonary artery 
pressure
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The main role of the TAVI team is a thorough patient 
assessment, estimation of benefits and risks of all available 
treatment strategies, and finally, deciding on the optimal 
destination therapy (conservative treatment, aortic balloon 
valvuloplasty, SAVR, or TAVI). The TAVI team may define 
the optimal access, type of anaesthesia, the choice and size 
of bioprostheses, the role of TAVI operators, and the type 
of postoperative care and its location in cardiac surgery or 
cardiology departments. We recommend briefings on the 
management of potential procedural complications before 
every procedure. Such a strategy, summing up decisions and 
describing procedural scenarios, increase the team’s prepara-
tion for the planned therapy. 
TAVI team meetings should be regular in every TAVI 
centre, with official dates known to referring physicians. Joint 
decisions should be communicated to the patient, and the 
physician involved in the treatment process. We recommend 
designing and using dedicated TAVI templates, simplifying and 
speeding the patient referral, the risk assessment, and decision 
making on the TAVI procedure (Appendix 1–3). 
Preprocedural management
A member of the TAVI team should provide necessary infor-
mation to the TAVI patient and the family on preparation for 
the procedure, its expected outcomes, and risks involved. 
The timing of the patient admission depends on the clini-
cal status and necessary diagnosis. It should allow planning 
of the drug therapy and estimation of the degree and type 
of potential cardiac arrhythmias and abnormalities of the 
conduction system. If right ventricular pacing is planned 
during the TAVI procedure in patients with an implantable 
cardioverter-defibrillator device, we recommend modifica-
tions to its settings beforehand. 
TAVI procedure
The TAVI procedure is performed by a team of operators: 
interventional cardiologists and/or cardiac surgeons. All 
operators involved should be certified in TAVI by their cor-
responding scientific societies: the ACVI for interventional 
cardiologists and the Polish Society of Cardio-Thoracic Sur-
geons for cardiac surgeons. 
To increase the safety of the operated patient, we recom-
mend that TAVI be performed jointly by a certified interven-
tional cardiologist and a certified cardiac surgeon. 
Choosing the optimal type of anaesthesia, obtaining 
a safe vascular access, and setting the best C-arm projec-
tion for fluoroscopy are the first, crucial stages of the TAVI 
procedure. If peripheral access is planned in patients with 
severe atherosclerosis, we recommend the direct assistance 
of a vascular surgeon during the procedure. 
Further, a stiff wire is passed through the aortic valve to 
the left ventricle, supporting the aortic balloon placement 
(used during an elective valvuloplasty) and the TAVI system. 
The aortic balloon valvuloplasty is performed most frequently 
during a rapid pacing of the right ventricle, usually at the rate 
of 160–200 bpm. Such stimulation allows for reducing the 
systolic pressure in the left ventricle and its stroke volume. De-
pending on the patient risk profile, the amount of calcification, 
and the annulus sizing precision, the balloon valvuloplasty 
may often be skipped [78]. The implantation technique of 
the aortic bioprosthesis varies with its type and construction. 
Balloon-expandable valves should be implanted during a rapid 
pacing of the right ventricle, while such stimulation is optional 
for self-expandable prostheses. In difficulties of valve stabili-
sation, fast pacing at the rate of 120–140 bpm may help to 
achieve an accurate implantation position [11]. After the valve 
deployment, its location in the surrounding anatomy, and the 
function and presence of PVL should be assessed by angiogra-
phy and echocardiography. If the paravalvular regurgitation is 
severe, the bioprosthesis may be post-dilated with a correctly 
sized aortic balloon, at the increased risk of valve malposi-
tion. If PVL is related to an incorrect valve position, further 
decisions should be based on precise benefit-risk calculations 
[89]. The implanted bioprosthesis may be repositioned or 
sealed by implantation of the second aortic prosthesis in the 
required aortic position, or managed by surgical intervention.
If TAVI is followed by a haemodynamic patient insta-
bility or ECG patterns of acute myocardial ischaemia, we 
recommend performing an urgent coronary angiography 
to assess patency of coronary arteries. Their occlusion is 
a rare but life-threatening complication. It requires imme-
diate action to restore the myocardial blood supply with 
either percutaneous coronary angioplasty or a relocation 
of the aortic bioprosthesis. In any sudden worsening of 
the patient’s clinical status, the team should rule out aortic 
annulus rupture, acute cardiac tamponade, or other major 
vascular complications that require prompt management. 
Therefore, we recommend that an interventional cardiologist 
and a cardiac surgeon be present in the TAVI centre during 
each TAVI procedure. 
The last stages of TAVI are the achievement of full hae-
mostasis at puncture sites, confirmation of stable patient’s 
clinical status and his/her safe transfer to a postoperative, 
intensive cardiology or cardiac surgery care unit. Any active 
bleeding at the site of the puncture, arterial dissection, or 
its occlusion should be promptly managed with peripheral 
balloons, stents, or stent-grafts sized according to the vessel 
diameter. In the presence of serious complications, vascular 
surgery is warranted to save the affected artery. 
Post-procedural management
The aims of the post-procedural management are prompt 
patient mobilisation and autonomy as well as monitoring and 
treatment of potential procedural complications. The course 
of postoperative surveillance over TAVI patients differs from 
cardiac surgery and requires a dedicated care pathway in the 
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TAVI centre. The most common problems occurring during 
this phase are: bleeding or vascular complications, cardiac 
arrhythmias, stroke, and acute heart or respiratory failure.
Patients should remain in the intensive postoperative care 
unit or the intensive cardiology care unit for at least one night 
after TAVI. A reasonably quick patient transfer to a step-down 
unit enables their earlier mobilisation, self-care, and feeding, re-
sulting in shortening the length of hospital stay (LOS). In advanced 
centres, the mean LOS of an uncomplicated TAVI is 2–5 days 
for transfemoral approach and 4–7 days for other access sites 
used [14]. Based on POL-TAVI registry reports, the mean LOS 
of an uncomplicated TAVI procedure in Poland is seven days.
Cardiac conduction disturbances
Disturbances of the cardiac conduction system are relatively 
common after TAVI. Such complications are precipitated by 
the anatomical neighbourhood of the aortic valve and the 
bundle of His and its branches. Reported postprocedural rates 
of pacemaker implantation after TAVI range from 17.5% in 
the German GARY registry, 17.4% in the FRACE-2 registry to 
11.0% in the American Transcatheter Valve Therapy Registry 
[101–105]. 
Prognostic factors. Known factors of a new-onset cardiac 
conduction abnormalities after TAVI are: 
 — male sex;
 — the presence of cardiac conduction disturbances be-
fore TAVI:
• right bundle branch block,
• left anterior hemiblock,
• atrioventricular block (AVB) type I;
 — TAVI in the native aortic valve (unlike the Valve-in-Valve 
implantation);
 — porcelain aorta [106, 107].
The following risk factors are modifiable: 
 — the kind of TAVI bioprosthesis (self-expandable > bal-
loon-mounted);
 — aortic balloon valvuloplasty;
 — the depth of valve implantation below the aortic annulus 
(≥ 6 mm) [106, 108].
The frequency of new LBBB or pacemaker implantation 
is significantly higher in patients treated using self-expandable 
TAVI systems in comparison to balloon-mounted ones (aver-
age LBBB rates 48% and 14%, new pacemakers 28% and 
6%, respectively) [101, 108]. In the CHOICE randomised 
clinical trial, 37.6% of patients with self-expandable TAVI 
bioprosthesis required pacemaker implantation, compared to 
17.3% of patients treated with a balloon-mounted biopros-
thesis (p < 0.001) [65]. The introduction of newer generation 
TAVI systems has not lowered the rate of newly implanted 
pacemakers [102]. 
Recommendations. Cardiac arrhythmias and conduction 
disturbances are frequent in populations of patients currently 
referred to TAVI. Therefore, we recommend that 24-h ECG 
monitoring and its detailed analysis be performed before the 
TAVI procedure. Current guidelines do not recommend a pro-
phylactic implantation of pacemakers based on the existence 
of risk factors for conduction defects. However, early detec-
tion of such defects allows shortening of the time needed for 
decision-making if such complications occur after TAVI [109]. 
The ESC guidelines on cardiac pacing and cardiac resyn-
chronisation therapy recommend patient observation and 
monitoring up to seven days before deciding on the implanta-
tion of cardiac pacemakers in patients with the occurrence of 
an advanced or complete AVBs after TAVI (recommendation 
level 1 C) [110]. In the case of a complete AVB with a low 
rate escape rhythm, the time of monitoring may be shortened, 
due to a low probability of recovery. Unfortunately, current 
registry data indicate that clinical practice does not follow 
the published guidelines: 33% of pacemaker implantations 
occur in the first 24 h, and 50% of them in the first 48 h, after 
TAVI [109, 111]. 
The occurrence of the sick sinus syndrome with sympto-
matic bradycardia after TAVI, without a complete AVB, is not 
an indication for pacemaker implantation. On the contrary, the 
presence of the new LBBB after TAVI increases the risk of late, 
advanced AVB by more than three-fold, especially in patients 
with a QRS duration > 160 ms [112]. Electrotherapy should 
be considered in this group of patients until new evidence from 
randomised trials appears [112, 113]. The algorithm of recom-
mended diagnosis and treatment of TAVI-qualified patients with 
conduction abnormalities is presented in Figure 3.
Bioprosthetic transcatheter valve dysfunction
Recommendations on diagnosis and treatment of thrombotic 
complications after TAVI are based on empirical data because 
the frequency of leaflet thrombosis in TAVI devices is not 
precisely known. In the randomised PARTNER and CoreValve 
trials the occurrence of leaflet thrombosis was not reported. 
In two multicentre registries it was observed in 0.76% and 
0.61% of patients, most often in the first three months after 
TAVI [114, 115]. Routine MSCT examination performed in 
the three months after TAVI allowed for detection of leaflet 
thrombosis in 6.9% of patients. The recognised predictive 
factors for transcatheter aortic valve dysfunction were large 
size of the prosthesis and lack of oral anticoagulation (OAC) 
after TAVI [116]. Current classification of bioprosthetic valve 
thrombosis is based on its timing or diagnostic certainty, 
assessed with clinical, imaging, or pathological criteria 
(Tables 2 and 3) [117].
For prevention of thromboembolic events after TAVI, 
European and American cardiology societies recommend 
dual antiplatelet therapy with aspirin (75–100 mg daily) indefi-
nitely and clopidogrel (75 mg daily) given for 1–6 months. The 
Canadian Cardiovascular Society supports clopidogrel 
withdrawal 1–3 months after the procedure, which corre-
sponds to the current clinical practice in Poland. Based on 
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Figure 3. Recommended diagnosis and treatment of conduction abnormalities in patient qualified to transcatheter aortic valve 
implantation (TAVI); ECG — electrocardiogram; LAHB — left anterior hemiblock; LBBB — left bundle branch block; RBBB — right 
bundle branch block
reports of high bleeding rates in patients undergoing TAVI 
in Poland, its authors recommend individual evaluation of 
double antiplatelet therapy (DAPT) requirements vs. single 
antiplatelet therapy (SAPT). They also note that antiplate-
let monotherapy, preferably with aspirin, could minimise 
bleeding complications, without increasing rates of early 
dysfunction of TAVI bioprosthesis [118, 119]. In patients 
with indications to OAC, we recommend a combination 
of OAC and SAPT (clopidogrel or aspirin) for 1–3 months 
[13, 14, 17–19, 83, 101, 120].
The recommended antiplatelet and antithrombotic ther-
apy after TAVI, based on comorbidities and patient bleeding 
risk, is presented in Tables 4 and 5 [121–124]. Publication of 
randomised clinical trials evaluating optimal antiplatelet and 
antithrombotic therapy after TAVI (novel oral anticoagulants 
[NOAC], and their pairing with ticagrelor), the introduction of 
new stents, as well as the publication of new guidelines on the 
Table 2. Temporal classification of bioprosthetic valve thrombosis
Classification Time of onset after TAVI
Acute 0–3 days
Subacute 4 days – 3 months
Late 3 months – 1 year
Very late > 1 year
Table 3. Classification of bioprosthetic valve thrombosis based on diagnostic certainty
Diagnostic  
certainty 
Clinical symptoms MSCT Echocardiography Pathomorphology
Definite Regression of new-onset 
heart failure symptoms 
after initiation  
of anticoagulation therapy
Reduced leaflet motion
Hypoattenuated leaflet 
thickening
Visualisation of thrombosis
Regression of elevated 
mean gradient < 10 mm Hg 
after oral anticoagulation 
therapy
Evidence of device  
thrombosis on examination 
of tissue samples retrieved 
during cardiac surgery  
or autopsy
Probable Acute heart failure  
symptoms
Reduced leaflet motion Increase in mean  
gradient > 10 mm Hg
–
Possible Stroke or arterial embolism 
after TAVI, after exclusion 
of other causes
– – –
MSCT — multislice computed tomography; TAVI — transcatheter aortic valve implantation
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use of dual antiplatelet therapy may modify our current rec-
ommendations. Nonetheless, we advise taking an individual 
approach to patients who are qualified to TAVI, considering 
their increased bleeding and thrombotic risk. 
Table 4. Antiplatelet therapy in patients with sinus rhythm, who are qualified to transcatheter aortic valve implantation (TAVI)
Indications other  
than TAVI
Therapy Before  
TAVI
≤ 3 months  
after TAVI
> 3 months  
after TAVI
None – SAPT (ASA*) for 48 h SAPT (ASA*) Lifelong SAPT (ASA*)
Lifelong SAPT (ASA*)
Lifelong SAPT (ASA*)
Coronary artery disease SAPT (ASA*) SAPT (ASA*) SAPT (ASA*)
Elective PCI before TAVI DAPT1 SAPT (ASA*)  
for 5–7 days
SAPT (ASA*)/DAPT1  
if PCI soon after TAVI
ACS before TAVI DAPT2 SAPT (ASA*) for 
5–7 days/DAPT2
SAPT (ASA*)/DAPT2 DAPT2 < 6 months,  
followed by lifelong  
SAPT (ASA*)
ACS — acute coronary syndrome; ASA — acetylsalicylic acid; DAPT — double antiplatelet therapy; PCI — percutaneous coronary intervention; 
SAPT — single antiplatelet therapy; *Preferred: (1) DAPT for 1 to 6 months following PCI, depending on the type of stent used as well as the risk 
of thrombosis and bleeding. Potent P2Y12 inhibitors (prasugrel, ticagrelor) should not be used. Reduce to SAPT 5–7 before TAVI. If possible, defer 
TAVI > 1 month after PCI; (2) DAPT for 3 to 6 months following PCI. Potent P2Y12 inhibitors (prasugrel, ticagrelor) should not be used. Reduce  
to SAPT 5–7 before TAVI. If possible, defer TAVI until DAPT termination
Table 5. Antiplatelet and antithrombotic therapy in patients with atrial fibrillation (AF), who are qualified to transcatheter aortic 
valve implantation (TAVI)
Indications other  
than TAVI
Therapy Before TAVI ≤ 3 months  
after TAVI
> 3 months 
after TAVI
AF VKA/NOAC VKA: stop (INR 1.0–1.3), LMWH  
bridging may be considered
NOAC: stop 48–72 h before TAVI, 
depending on agent and creatinine 
clearance. LMWH bridging in  
very high stroke risk
VKA
Consider 
LMWH bridging until  
therapeutic INR achieved
VKA/NOAC1
AF + elective  
PCI before TAVI
VKA/NOAC  
+ DAPT2
VKA: stop (INR 1.0–1.3), LMWH  
bridging may be considered
NOAC: stop 48–72 h before TAVI, 
depending on agent and creatinine 
clearance. LMWH bridging in  
very high stroke risk
+
SAPT (ASA*) for 5–7 days
VKA 
Consider LMWH bridging
until therapeutic INR achieved 
+ 
SAPT (ASA*)/consider DAPT2  
if PCI soon after TAVI
VKA/NOAC1
+
SAPT  
≤ 6 months  
after TAVI
AF + ACS  
before TAVI
VKA/NOAC  
+ DAPT
VKA: stop (INR 1.0–1.3), LMWH  
bridging may be considered.
NOAC: stop 48–72 h before TAVI,  
depending on agent and creatinine  
clearance. LMWH bridging in  
very high stroke risk
+
SAPT (ASA*) for 5–7 days
VKA 
Consider LMWH bridging until 
therapeutic INR achieved 
+
SAPT (ASA*)/consider DAPT2 if 
PCI soon after TAVI
VKA/NOAC1
+
SAPT  
≤ 6 months  
after TAVI
ACS — acute coronary syndrome; ASA —  acetylsalicylic acid; DAPT — double antiplatelet therapy; INR — international normalised ratio; LMWH 
— low molecular weight heparin; NOAC — novel oral anticoagulants; PCI — percutaneous coronary intervention; SAPT — single antiplatelet 
therapy; VKA — vitamin K antagonists; *Preferred: (1) VKA are preferred due to insufficient NOAC evidence. Until the publication of randomised 
trials, starting NOAC may be considered 3–6 months after TAVI; (2) DAPT for 1 to 6 months following PCI, depending on the type of stent used as 
well as the risk of thrombosis and bleeding. Potent P2Y12 inhibitors (prasugrel, ticagrelor) should not be used. Reduce to SAPT 5–7 before TAVI.  
If possible, defer TAVI > 1 month after PCI; (3) Defer TAVI until DAPT termination, if possible. Otherwise, maintain DAPT for 3–6 months after ACS 
in patients with high thrombotic risk. Potent P2Y12 inhibitors (prasugrel, ticagrelor) should not be used
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Management of transcatheter aortic valve thrombosis de-
pends on the severity of heart failure symptoms and evidence 
derived from echocardiography or MSCT. The proposed algo-
rithm for the diagnosis and treatment of transcatheter aortic 
valve thrombosis is presented in Figure 4 [117]. 
Endocarditis. The risk of prosthetic valve endocarditis is 
present in all patients after SAVR or TAVI. Therefore, primary 
and secondary prevention is vital in all TAVI patients as indi-
cated in the ESC guidelines for the management of infective 
endocarditis [125]. 
Echocardiography follow-up. TTE should be performed 
in all TAVI patients before hospital discharge, with special 
attention paid to transvalvular pressure gradient, effective 
valve area, and degree and location of PVL. Follow-up TTE 
examinations should be planned at one-month follow-up visit 
after TAVI and every year thereafter [126]. The intervals should 
be shorter in patients with increased risk of early bioprosthesis 
degeneration: high gradient, PVL, renal failure, and at every 
new onset of heart failure (Fig. 5) [117].
TAVI OPERATORS
TAVI operator requirements
The status of an independent TAVI operator may be given 
to interventional cardiologists who comply with the ACVI 
certification requirements, and to cardiac surgeons who have 
received TAVI Skill Certificate issued by the Polish Society of 
Cardio-Thoracic Surgeons, allowing them to perform these 
procedures using all available access sites. 
To guarantee patient safety, we recommend the presence 
of two certified TAVI operators during the procedure: an in-
terventional cardiologist and a cardiac surgeon. The following, 
detailed recommendations on TAVI training and skills refer to 
both operators involved.  
Interventional cardiologist
To receive an Independent TAVI Operator Certificate, 
an interventional cardiologist should fulfil the following 
criteria: 
1. Board-certified specialisation in cardiology.
2. A valid certificate of the Independent Interventional 
Cardiology Operator issued by the ACVI.
3. The first or the second operator experience of: 
 — at least 10 TAVI procedures performed under the su-
pervision of an independent TAVI operator/proctor;
 — followed by at least 20 TAVI procedures per-
formed independently;
 — at least 10 TAVI procedures performed yearly af-
terwards;
Figure 4. Recommendations on the diagnosis and management of transcatheter aortic valve thrombosis; IV — intravenous; 
MSCT — multislice computed tomography; NYHA — New York Heart Association functional class; OAC — oral anticoagulation; 
SAVR — surgical aortic valve replacement; TEE — transoesophageal echocardiography; TTE — transthoracic echocardiography
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 — after the total of 50 TAVI procedures performed, the 
Independent TAVI Operator Certificate becomes 
permanent. 
4. Formal training on the use of available TAVI systems, 
including tutoring in an experienced TAVI centre. At 
a minimum, the training should include educational 
presentations and participation in at least two TAVI pro-
cedures performed in a reference TAVI centre. 
TAVI is a complex procedure, requiring skilful manage-
ment of various complications. Therefore, interventional 
cardiologists should take part in courses and practical 
training in:
 — interventional treatment of structural heart diseases;
 — interventional diagnosis and treatment of peripheral 
artery diseases;
 — peripheral artery access site management and closure;
 — extracorporeal membrane oxygenation (ECMO) place-
ment and patient management [13, 15, 17, 18, 21, 83, 
90, 95, 127–129]. 
Cardiac surgeon
A cardiac surgeon — an Independent TAVI Operator — should 
fulfil the criteria defined by the Skill Certificate, issued specifi-
cally by the Polish Society of Cardio-Thoracic Surgeons, after the 
following experience and skills in TAVI have been documented:
 — a board-certified specialisation in cardiac surgery;
 — operator experience in surgical valve replacement, with 
the minimum of 300 structural heart operations;
 — operator experience in surgical valve reoperations, with 
the minimum of 25 reoperations;
 — ECMO placement and patient management;
 — participation in TAVI training, as recommended by the 
Polish Society of Cardio-Thoracic Surgeons or Euro-
pean societies: EACTS/ESC/ESCVS, or other specialisa-
tion courses;
 — operator experience in at least 20 TAVI procedures [13, 
15, 17, 18, 21, 83, 129–131];
 — at least 10 TAVI procedures performed yearly afterwards;
 — formal training on the use of available TAVI systems, 
including a practice in an experienced TAVI centre. At 
a minimum, the training should include educational pres-
entations and participation in at least two TAVI procedures 
performed in a reference TAVI centre [90, 95, 127, 128].
TAVI CENTRE
Institutional and operator experience is crucial for securing 
optimal outcomes in patients referred to TAVI. The introduc-
tion of the modern TAVI technology to treat high-risk patients 
in multispecialty hospitals with established TAVI teams allows 
reduction of the number of procedural complications in the 
challenging treatment group. Such a policy ensures optimal 
decision making during patient referral to TAVI. Also, it guar-
antees skilful procedural performance and high quality of care 
during hospitalisation and after the discharge.
The TAVI programme should be conducted in hospitals 
with accredited interventional cardiology catheterisation labs 
(class C accreditation awarded by ACVI), with a cardiac surgery 
department on site.
Moreover, the TAVI centre should fulfil the following 
criteria [13, 15, 17, 18, 21, 83, 90, 95, 132]:
 — perform no less than 1000 coronary angiography and 
no less than 700 coronary angioplasty procedures in 
a calendar year;
 — perform at least 150 SAVR in a calendar year, including 
at least 15 SAVR in high-risk patients (STS ≥ 8%, Euro-
SCORE II ≥ 8%);
Figure 5. Recommended bioprosthetic valve imaging follow-up after transcatheter aortic valve implantation; MSCT — multislice 
computed tomography; TEE — transoesophageal echocardiography; TTE — transthoracic echocardiography
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 — employ at least two interventional cardiologists and at 
least two cardiac surgeons, all certified in TAVI by ap-
propriate scientific societies;
 — take part in the Polish TAVI Registry, POL-TAVI, with 
systematic data contribution and monitoring of its com-
pleteness (https://poltavi.pl);
 — enrol in the Polish Interventional Cardiology TAVI database, 
administered by ACVI (PICTS, available online: http://aisn.
pl) and the TAVI centre address database, managed by the 
Polish Society of Cardio-Thoracic Surgeons.
TAVI centres should contain the following facilities [13, 
15, 17, 18, 21, 83]:
 — cardiac catheterisation laboratory or hybrid cath lab/op-
erating room equipped with a fixed table, fluoroscopy 
system, and pressure monitoring systems;
 — the implantation room must have sufficient space to 
accommodate all personnel involved in TAVI procedure 
and the necessary anaesthesiology, echocardiography, 
and cardiopulmonary bypass equipment, which may be 
used during TAVI;
 — cardiac surgery department on site, performing at least 
150 SAVR in a calendar year with mortality < 6% and 
approximately 10% of SAVR reoperations;
 — non-invasive cardiology and vascular imaging laboratories:
• echocardiography lab, performing transthoracic and 
transoesophageal examinations. Its staff must be 
trained in imaging of structural heart diseases and 
their interpretation,
• access to a vascular laboratory capable of performing 
vascular imaging examinations and their interpretation,
• access to a computed tomography laboratory, 
capable of performing heart and vessel computed 
tomography imaging and its interpretation;
 — catheterisation lab/operating room certified for pacemak-
er and implantable cardiac defibrillator implantations; 
 — essential equipment to treat various TAVI complications, 
such as heart conduction abnormalities, aortic and 
peripheral artery perforation, cardiac tamponade, and 
cardiogenic or hypovolaemic shock;
 — ECMO availability and TAVI team experience in its im-
plantation and management in life-threatening conditions;
 — (Cardiology) Intensive Care Unit or Postoperative Inten-
sive Care Unit present on-site;
 — renal replacement therapy available on-site.
To increase standards of TAVI procedure, we recommend:
 — integration of ventilation and air conditioning laminar 
flow diffusers;
 — high-output lighting systems for the operating field.
TAVI outcomes
Outcomes of TAVI therapy strongly depend on the institutional 
experience gained and individual number of procedures 
performed by TAVI operators. To ensure a high procedural 
safety profile and quality of care, TAVI centres should aim 
to achieve the following level of proficiency, including the 
number of procedures performed and their outcomes levels 
[13–15, 17, 18, 21, 83, 90, 95, 132]:
 — ≥ 40 TAVI procedures per calendar year;
 — 30-day all-cause mortality < 5%;
 — 30-day stroke (transient ischaemic attack included) < 5%;
 — major vascular complications < 3%;
 — continuous reporting and integrity of data in the Pol-
ish TAVI Registry (POL-TAVI) including short-term and 
long-term follow-up;
 — 80% one-year patient survival rate in the last two years 
of the TAVI programme in the centre. 
TAVI REGISTRIES: ACCESSIBILITY  
AND SAFETY MONITORING
Transcatheter aortic valve implantation is a novel technology, 
requiring continuous evaluation of procedural safety as well 
as short- and long-term treatment outcomes. Multicentre 
TAVI registries are necessary to establish the efficacy of this 
therapy in specific indications. Also, they serve to document 
the TAVI experience in new clinical applications, in patients 
with different profile risks and treated with an array of TAVI 
systems. Short- and long-term follow-up should allow assess-
ment of efficacy and safety of the novel therapy, including 
patient survival, follow-up of implanted bioprostheses for their 
degeneration, and observation of reintervention rates after 
TAVI [133]. Registry objectives may also include cost-effec-
tiveness surveillance and comparison of the offered treatment. 
Registries should meet the set credibility criteria, assessed by 
internal as well as external monitoring and validation. Such 
hospital-independent comparisons with healthcare provider 
reimbursement reports ensure the highest quality assessment 
of the novel therapy. 
Observational data of all patients undergoing TAVI should 
be submitted and registered in the Polish cardiology and car-
diac surgery TAVI Registry (POL-TAVI). Its creation in 2012 was 
initiated by cardiac surgeons and cardiologists in cooperation 
with the Ministry of Health and the National Health Fund 
and supported by the Polish Cardiac Society and The Polish 
Society of Cardio-Thoracic Surgeons. Since then POL-TAVI 
has gathered significant demographic data on patient refer-
ral, in-hospital success and complications rates, as well as 
short- and long-term outcomes in Poland [134]. With bi- 
-annual internal and external auditing, it meets strict criteria 
set for independent national registries.
TAVI COST
The mean cost of TAVI treatment is currently five-times higher 
than SAVR, a situation driven mainly by the cost of the bio-
prosthesis. At the same time, the valuation of TAVI procedure 
and hospitalisation in Poland is lower than in other European 
Union countries. Based on the experience of many Polish 
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centres, the current reimbursement scheme, covering solely 
cardiac surgery departments at small procedural valuation 
level, does not allow the budget of TAVI hospitalisation to be 
balanced. Importantly, TAVI saves lives and decreases rehos-
pitalisation rates and the length of hospital stay in patients 
disqualified from SAVR by TAVI teams [6, 91]. In high- and 
intermediate-risk patients, shortening the intensive care unit 
stay and the total duration of TAVI hospitalisation may be 
beneficial, both clinically and economically.
The growth of Polish TAVI team experience supported 
by technology advances in imaging and construction of tran-
scatheter valves will result in better diagnosis and selection of 
patients, with a further reduction of complication rates. So far, 
the economic superiority of TAVI in Poland has been proven in 
prohibitive and high-risk patients only. Still, with significantly 
shorter durations of TAVI procedure, the postoperative care, 
and the total hospital stay, the cost-effectiveness of TAVI may 
become competitive to cardiac surgery — providing a lower 
cost of aortic bioprosthesis and readjustment of the compensa-
tion for TAVI hospitalisation. As the number of Polish patients 
on TAVI waiting lists is increasing, a nationwide quality-adjust-
ed life year (QALY) assessment and cost-effectiveness analysis 
(CEA) is required to address the above problems [12].
SUMMARY
TAVI is a modern and efficient therapy dedicated to specific 
groups of patients with aortic valve diseases, especially those 
at high risk of conventional surgery.
TAVI is a lifesaving treatment for non-operable patients. In 
high- and intermediate-risk groups, results of TAVI and car-
diac surgery are comparable. Early experience indicates the 
usefulness of this therapy in patients with degenerated aortic 
bioprostheses. Such remarkable outcomes can be achieved as 
long as TAVI patients are qualified by dedicated TAVI teams 
and operated by highly skilled TAVI operators: interventional 
cardiologists and cardiac surgeons. The situation will be pos-
sible with continuous education and shared support present 
among cardiologists, cardiac surgeons, and other physicians 
involved in the treatment of patients with structural heart 
diseases in Poland. In the wake of population ageing, medi-
cal, organisational, and economic experts participating in the 
development of this innovative therapy in Poland should act 
together to increase the number of TAVI procedures and its 
cost-effectiveness to average European levels. Such actions 
should rely on results of non-commercial registries of TAVI 
quality, accessibility, and safety, including POL-TAVI and the 
National Registry of Cardiac Surgery Procedures (KROK). 
EXPERT CONSENSUS OUTLINE
Current evidence
TAVI is a safe and effective therapy in patients with significant 
and symptomatic AS:
 — prohibitive risk/inoperable patients: TAVI is superior to 
medical treatment (PARTNER 1 Study Cohort B, Cor-
eValve US Pivotal Trial Extreme Risk Iliofemoral Study);
 — high-risk patients: TAVI is non-inferior to SAVR (PART-
NER 1 Study Cohort A, CoreValve US Pivotal Trial 
High-Risk Study);
 — intermediate-risk patients: TAVI and SAVR are equally 
effective. In transfemoral approach, TAVI is superior to 
SAVR (PARTNER 2 A Study, SURTAVI Study);
 — low-risk patients: TAVI is non-inferior to SAVR (NOTION).
TAVI is associated with a better or equal effective orifice 
area and mean pressure gradient of implanted biological pros-
thesis than after SAVR across all patient risk groups (PARTNER 1, 
CoreValve High-Risk, PARTNER 2, SURTAVI, NOTION). 
These parameters remained unchanged in prohibitive risk 
(PARTNER 1 Study, five-year follow-up), high-risk (PARTNER 1 
Study: five-year follow-up, CoreValve High-Risk Study: 
three-year follow-up), moderate-risk (SURTAVI, one-year 
follow-up), and low-risk patients (NOTION, two-year 
follow-up). 
Recommendations for treatment of patients  
with significant aortic valve stenosis
1. The decision on the optimal treatment of patients with 
severe, symptomatic aortic valve disease should be made 
by a multidisciplinary TAVI team experienced in patient 
screening and management during TAVI procedures. It 
should include at least: two certified TAVI operators (an 
interventional cardiologist and a cardiac surgeon), an 
echocardiographer, and an anaesthesiologist [22, 90].
2. Prohibitive-risk patients should be qualified to TAVI first 
[6, 28, 98].
3. High-risk patients (STS ≥ 8%, EuroSCORE II ≥ 8%, log 
EuroSCORE ≥ 20%) should be qualified to TAVI first 
[5, 8, 9, 53].
4. The decision on the treatment of lower-risk groups of 
patients should depend on the TAVI team. TAVI should 
be considered in the following populations:
 — intermediate-risk patients [5, 7–9, 53];
 — patients aged ≥ 85 years [5, 8, 9, 53];
 — patients with a degenerated aortic valve bioprosthesis 
or a history of previous cardiac operations increasing 
the reoperation risk [42, 92–94];
 — patients with the following risks of cardiac surgery:
• extensive calcification of the ascending aorta 
(porcelain aorta),
• history of chest radiotherapy,
• chest deformations,
• liver failure,
• osteoporosis,
• active cancer,
• frailty syndrome;
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5. Low-risk patients < 75 years old (STS < 4%, EuroSCORE II 
< 4%, log EuroSCORE < 10%) should be first referred 
to SAVR [9, 95].
6. In unstable patients with severe aortic stenosis and with 
high operative risk or awaiting a non-cardiac operation, 
aortic balloon valvuloplasty should be considered alone, 
or as a bridge to SAVR or TAVI therapy. 
7. In unstable patients already qualified to TAVI, aortic bal-
loon valvuloplasty should be considered as a bridge to 
a planned TAVI procedure. 
8. Aortic balloon valvuloplasty can also be considered as 
a palliative treatment in patients with multiple risk fac-
tors rendering cardiac surgery risk prohibitive and TAVI 
impossible. 
9. Patients with a predicted poor outcome, includ-
ing < 1-year survival, should be qualified to a palliative 
treatment (conservative or aortic balloon valvuloplasty).
TAVI centres and operators
1. On-site interventional cardiology cath-lab accredited 
with the ACVI class C.
2. On-site cardiac surgery department.
3. Imaging laboratory (echocardiography and MSCT or 
magnetic resonance laboratory).
4. ≥ Two TAVI-certified interventional cardiologist em-
ployed.
5. ≥ Two TAVI-certified cardiac surgeons employed.
6. ≥ Two anaesthesiologists trained in TAVI employed.
7. Established TAVI team with regular consultation meetings.
8. ≥ 40 TAVI procedures in a calendar year.
9. Participation in the POL-TAVI registry.
10. TAVI centres and operators registered in TAVI databases 
of the ACVI and the Polish Society of Cardio-Thoracic Sur-
geons.
11. Independent TAVI operators: 
 — interventional cardiologist: a board-certified cardi-
ologist holding a valid Independent TAVI Operator 
Certificate issued by ACVI,
 — cardiac surgeon: a board-certified cardiac surgeon 
holding a valid TAVI Skills Certificate issued by the 
Polish Society of Cardio-Thoracic Surgeons.
TAVI procedure
1. Performed by certified TAVI operators: interventional car-
diologists and/or cardiac surgeons. For increased patient 
safety, TAVI should be performed jointly by a certified 
interventional cardiologist and a certified cardiac surgeon.
2. Hybrid room or cath-lab in close proximity to a cardiac 
surgery theatre.
3. ECMO availability, with TAVI team experience in ECMO 
placement and patient management.
4. Conscious sedation preferred over general anaesthesia.
5. Transfemoral access preferred over other TAVI routes.
Post-procedural care
1. Patient supervision in Intensive Therapy Department or 
Intensive Coronary Care Unit ≥ 24 h after TAVI.
2. Telemetry ≥ 24 h after TAVI, depending on the presence 
of cardiac arrhythmias and conduction abnormalities or 
their risk factors.
3. Direct access to a vascular surgeon, neurologist, radiolo-
gist, surgeon for an urgent consultation.
4. Direct access to echocardiography and MSCT imaging.
5. Dedicated diagnostic and therapeutic pathway for pa-
tients with cardiac conduction abnormalities.
6. Follow-up visits: at least one-month and one-year after 
TAVI, every year thereafter (clinical status, QoL, echo-
cardiographic examination).
Conflict of interest: Marek Grygier: research support, con-
sultation fees, proctor: Medtronic, research support, consul-
tation fees, proctor, speakers honoraria: Boston Scientific; 
Maciej Lesiak: speakers honoraria: Boston Scientific; Adam 
Witkowski: proctors fees: Medtronic, speakers fees: Medtronic, 
Boston Scientific, Edwards; Wojciech Wojakowski: Medtronic 
Advisory Board, Edwards Life Sciences: lecture honorarium; 
Michał Zembala: consultant for Symetis SA, Vascutek Terumo, 
Abbott, AtriCure Inc.
References
1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart 
diseases: a population-based study. Lancet. 2006; 368(9540): 
1005–1011, doi:10.1016/S0140-6736(06)69208-8, indexed in 
Pubmed: 16980116.
2. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of 
very severe aortic stenosis. Circulation. 2010; 121(1): 151–156, 
doi:10.1161/CIRCULATIONAHA.109.894170, indexed in Pub-
med: 20026771.
3. Eveborn GW, Schirmer H, Heggelund G, et al. The evolving 
epidemiology of valvular aortic stenosis. the Tromsø study. 
Heart. 2013; 99(6): 396–400, doi: 10.1136/heartjnl-2012-302265, 
indexed in Pubmed: 22942293.
4. Iung B, Baron G, Butchart EG, et al. A prospective survey of 
patients with valvular heart disease in Europe: The Euro Heart 
Survey on Valvular Heart Disease. Eur Heart J. 2003; 24(13): 
1231–1243, doi: 10.1016/s0195-668x(03)00201-x.
5. Adams DH, Popma JJ, Reardon MJ, et al. U.S. CoreValve 
Clinical Investigators. Transcatheter aortic-valve replace-
ment with a self-expanding prosthesis. N Engl J Med. 2014; 
370(19): 1790–1798, doi: 10.1056/NEJMoa1400590, indexed in 
Pubmed: 24678937.
6. Leon MB, Smith CR, Mack M, et al. PARTNER Trial Investiga-
tors. Transcatheter aortic-valve implantation for aortic stenosis 
in patients who cannot undergo surgery. N Engl J Med. 2010; 
363(17): 1597–1607, doi: 10.1056/NEJMoa1008232, indexed in 
Pubmed: 20961243.
7. Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investiga-
tors. Transcatheter or Surgical Aortic-Valve Replacement in Inter-
mediate-Risk Patients. N Engl J Med. 2016; 374(17): 1609–1620, 
doi: 10.1056/NEJMoa1514616, indexed in Pubmed: 27040324.
8. Smith C, Leon M, Mack M, et al. Transcatheter versus Sur- 
gical Aortic-Valve Replacement in High-Risk Patients. New 
Engl J Med. 2011; 364(23): 2187–2198, doi:  10.1056/nejmoa 
1103510.
www.kardiologiapolska.pl
Transcatheter aortic valve implantation
957
9. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the 
management of valvular heart disease (version 2012): The Joint 
Task Force on the Management of Valvular Heart Disease of the 
European Society of Cardiology (ESC) and the European Asso-
ciation for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012; 
33(19): 2451–2496, doi: 10.1093/eurheartj/ehs109.
10. Herrmann HC, Han Y. Identifying patients who do not benefit 
from transcatheter aortic valve replacement. Circ Cardiovasc 
Interv. 2014; 7(2): 136–138, doi:  10.1161/CIRCINTERVEN-
TIONS.114.001410, indexed in Pubmed: 24737333.
11. Roy DA, Schaefer U, Guetta V, et al. Transcatheter aortic valve 
implantation for pure severe native aortic valve regurgitation. 
J Am Coll Cardiol. 2013; 61(15): 1577–1584, doi:  10.1016/j.
jacc.2013.01.018, indexed in Pubmed: 23433565.
12. Parma R, Dąbrowski M, Ochała A, et al. The Polish Interventional 
Cardiology TAVI Survey (PICTS): adoption and practice of trans-
catheter aortic valve implantation in Poland. Postepy Kardiol 
Interwencyjnej. 2017; 13(1): 10–17, doi: 10.5114/aic.2017.66181, 
indexed in Pubmed: 28344612.
13. Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic 
valve implantation: a Canadian Cardiovascular Society position 
statement. Can J Cardiol. 2012; 28(5): 520–528, doi: 10.1016/j.
cjca.2012.04.015, indexed in Pubmed: 22703948.
14. Hawkey MC, Lauck SB, Perpetua EM, et al. Transcatheter aortic 
valve replacement program development: recommendations for 
best practice. Catheter Cardiovasc Interv. 2014; 84(6): 859–867, 
doi: 10.1002/ccd.25529, indexed in Pubmed: 24760495.
15. Kuck KH, Hamm C. Executive summary of the position paper of 
the german cardiac society on quality criteria for the implementa-
tion of transcatheter aortic valve implantation (TAVI). Eur Heart J. 
2015; 36(6): 328–330.
16. Santoro G, Bedogni F, Ambrosini V, et al. SICI-GISE. [Trans-
catheter aortic valve implantation in patients with severe 
symptomatic aortic stenosis: position statement of the Italian 
Society of Interventional Cardiology (SICI-GISE) on minimum 
standards for hospitals and operators]. G Ital Cardiol (Rome). 
2012; 13(11): 772–776, doi: 10.1714/1168.12956, indexed in 
Pubmed: 23096589.
17. Walters DL, Webster M, Pasupati S, et al. Position statement for 
the operator and institutional requirements for a transcatheter 
aortic valve implantation (TAVI) program. Heart Lung Circ. 
2015; 24(3): 219–223, doi: 10.1016/j.hlc.2014.09.009, indexed 
in Pubmed: 25488705.
18. Tommaso C, Bolman R, Feldman T, et al. Multisociety (AATS, 
ACCF, SCAI, and STS) Expert Consensus Statement: Operator 
and Institutional Requirements for Transcatheter Valve Repair 
and Replacement, Part 1: Transcatheter Aortic Valve Replace-
ment. J Am Coll Cardiol. 2012; 59(22): 2028–2042, doi: 10.1016/j.
jacc.2012.02.016.
19. Achenbach S, Delgado V, Hausleiter J, et al. SCCT expert con-
sensus document on computed tomography imaging before 
transcatheter aortic valve implantation (TAVI)/transcatheter 
aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr. 
2012; 6(6): 366–380, doi:10.1016/j.jcct.2012.11.002, indexed in 
Pubmed: 23217460.
20. Campante Teles R, Gama Ribeiro V, Patrício L, et al. Position 
statement on transcatheter aortic valve implantation in Por-
tugal. Rev Port Cardiol. 2013; 32(10): 801–805, doi: 10.1016/j.
repc.2013.02.009, indexed in Pubmed: 23916790.
21. Kuck KH, Eggebrecht H, Elsässer A, et al. Qualitätskriterien 
zur Durchführung der kathetergestützten Aortenklappen-
implantation (TAVI). Der Kardiologe. 2016; 10(5): 282–300, 
doi: 10.1007/s12181-016-0082-4.
22. Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC Expert 
Consensus Decision Pathway for Transcatheter Aortic Valve 
Replacement in the Management of Adults With Aortic Stenosis: 
A Report of the American College of Cardiology Task Force on 
Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017; 
69(10): 1313–1346, doi: 10.1016/j.jacc.2016.12.006, indexed in 
Pubmed: 28063810.
23. Gersak B, Fischlein T, Folliguet TA, et al. Sutureless, rapid 
deployment valves and stented bioprosthesis in aortic valve 
replacement: recommendations of an International Expert Con-
sensus Panel. Eur J Cardiothorac Surg. 2016; 49(3): 709–718, 
doi: 10.1093/ejcts/ezv369, indexed in Pubmed: 26516193.
24. Englberger L, Carrel TP, Doss M, et al. Clinical performance of 
a sutureless aortic bioprosthesis: five-year results of the 3f En-
able long-term follow-up study. J Thorac Cardiovasc Surg. 2014; 
148(4): 1681–1687, doi: 10.1016/j.jtcvs.2014.03.054, indexed in 
Pubmed: 24787699.
25. Sadowski J, Kapelak B, Pfitzner R, et al. Sutureless aortic valve 
bioprothesis ‘3F/ATS Enable’--4.5 years of a single-centre experi-
ence. Kardiol Pol. 2009; 67(8A): 956–963.
26. Breitenbach I, Wimmer-Greinecker G, Bockeria LA, et al. Su-
tureless aortic valve replacement with the Trilogy Aortic Valve 
System: multicenter experience. J Thorac Cardiovasc Surg. 2010; 
140(4): 878–84, 884.e1, doi: 10.1016/j.jtcvs.2010.06.042, indexed 
in Pubmed: 20674945.
27. Kapadia SR, Leon MB, Makkar RR, et al. PARTNER trial investiga-
tors. 5-year outcomes of transcatheter aortic valve replacement 
compared with standard treatment for patients with inoper-
able aortic stenosis (PARTNER 1): a randomised controlled 
trial. Lancet. 2015; 385(9986): 2485–2491, doi:10.1016/S0140-
6736(15)60290-2, indexed in Pubmed: 25788231.
28. Popma J, Adams D, Reardon M, et al. Transcatheter Aortic 
Valve Replacement Using  a Self-Expanding Bioprosthesis in 
Patients With Severe Aortic Stenosis at Extreme Risk for Sur-
gery. J Am Coll Cardiol. 2014; 63(19): 1972–1981, doi: 10.1016/j.
jacc.2014.02.556.
29. Mack M, Leon M, Smith C, et al. 5-year outcomes of transcatheter 
aortic valve replacement or surgical aortic valve replacement 
for high surgical risk patients with aortic stenosis (PARTNER 
1): a randomised controlled trial. Lancet. 2015; 385(9986): 
2477–2484, doi: 10.1016/s0140-6736(15)60308-7.
30. Deeb G, Reardon M, Chetcuti S, et al. 3-Year Outcomes in 
High-Risk Patients Who Underwent Surgical or Transcatheter 
Aortic Valve Replacement. J Am Coll Cardiol. 2016; 67(22): 
2565–2574, doi: 10.1016/j.jacc.2016.03.506.
31. Mohr FW, Holzhey D, Möllmann H, et al. GARY Executive 
Board. The German Aortic Valve Registry: 1-year results from 
13,680 patients with aortic valve disease. Eur J Cardiothorac 
Surg. 2014; 46(5): 808–816, doi: 10.1093/ejcts/ezu290, indexed 
in Pubmed: 25079769.
32. Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI 
Investigators. Surgical or Transcatheter Aortic-Valve Replace-
ment in Intermediate-Risk Patients. N Engl J Med. 2017; 
376(14): 1321–1331, doi: 10.1056/NEJMoa1700456, indexed in 
Pubmed: 28304219.
33. Thyregod HG, Steinbrüchel DA, Ihlemann N, et al. Transcatheter 
Versus Surgical Aortic Valve Replacement in Patients With Se-
vere Aortic Valve Stenosis: 1-Year Results From the All-Comers 
NOTION Randomized Clinical Trial. J Am Coll Cardiol. 2015; 
65(20): 2184–2194, doi:10.1016/j.jacc.2015.03.014, indexed in 
Pubmed: 25787196.
34. Søndergaard L, Steinbrüchel D, Ihlemann N, et al. Two-Year 
Outcomes in Patients With Severe Aortic Valve Stenosis Random-
ized to Transcatheter Versus Surgical Aortic Valve Replacement. 
Circulation: Cardiovascular Interventions. 2016; 9(6): e003665, 
doi: 10.1161/circinterventions.115.003665.
35. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Fo-
cused Update of the 2014 AHA/ACC Guideline for the Manage-
ment of Patients With Valvular Heart Disease: A Report of the 
American College of Cardiology/American Heart Association 
Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 
www.kardiologiapolska.pl
Radosław Parma et al.
958
2017; 70(2): 252–289, doi: 10.1016/j.jacc.2017.03.011, indexed 
in Pubmed: 28315732.
36. Zhao ZG, Jilaihawi H, Feng Y, et al. Transcatheter aortic valve 
implantation in bicuspid anatomy. Nat Rev Cardiol. 2015; 
12(2): 123–128, doi:10.1038/nrcardio.2014.161, indexed in 
Pubmed: 25311233.
37. Yoon SH, Bleiziffer S, De Backer O, et al. Outcomes in transcath-
eter aortic valve replacement for bicuspid versus tricuspid aor-
tic valve stenosis. J Am Coll Cardiol. 2017; 69(21): 2579–2589, 
doi: 10.1016/j.jacc.2017.03.017, indexed in Pubmed: 28330793.
38. Kochman J, Huczek Z, Scisło P, et al. Comparison of one- and 
12-month outcomes of transcatheter aortic valve replacement in 
patients with severely stenotic bicuspid versus tricuspid aortic 
valves (results from a multicenter registry). Am J Cardiol. 2014; 
114(5): 757–762, doi:10.1016/j.amjcard.2014.05.063, indexed in 
Pubmed: 25037674.
39. Kochman J, Rymuza B, Huczek Z. Transcatheter aortic valve 
replacement in bicuspid aortic valve disease. Curr Opin Cardiol. 
2015; 30(6): 594–602, doi:  10.1097/HCO.0000000000000219, 
indexed in Pubmed: 26398414.
40. Thourani VH, Suri RM, Gunter RL, et al. Contemporary real-world 
outcomes of surgical aortic valve replacement in 141,905 low-risk, 
intermediate-risk, and high-risk patients. Ann Thorac Surg. 2015; 
99(1): 55–61, doi: 10.1016/j.athoracsur.2014.06.050, indexed in 
Pubmed: 25442986.
41. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, man-
agement, and clinical outcomes of coronary obstruction following 
transcatheter aortic valve implantation: insights from a large 
multicenter registry. J Am Coll Cardiol. 2013; 62(17): 1552–1562, 
doi: 10.1016/j.jacc.2013.07.040, indexed in Pubmed: 23954337.
42. Paradis JM, Del Trigo M, Puri R, et al. Transcatheter Valve-in-Valve 
and Valve-in-Ring for Treating Aortic and Mitral Surgical Pros-
thetic Dysfunction. J Am Coll Cardiol. 2015; 66(18): 2019–2037, 
doi: 10.1016/j.jacc.2015.09.015, indexed in Pubmed: 26516006.
43. Praz F, Windecker S, Huber C, et al. Expanding Indications of 
Transcatheter Heart Valve Interventions. JACC Cardiovasc Interv. 
2015; 8(14): 1777–1796, doi: 10.1016/j.jcin.2015.08.015, indexed 
in Pubmed: 26718509.
44. Sawaya FJ, Deutsch MA, Seiffert M, et al. Safety and Efficacy 
of Transcatheter Aortic Valve Replacement in the Treatment of 
Pure Aortic Regurgitation in Native Valves and Failing Surgical 
Bioprostheses: Results From an International Registry Study. 
JACC Cardiovasc Interv. 2017; 10(10): 1048–1056, doi: 10.1016/j.
jcin.2017.03.004, indexed in Pubmed: 28521923.
45. Franzone A, Piccolo R, Siontis GCM, et al. Transcatheter Aortic 
Valve Replacement for the Treatment of Pure Native Aortic Valve 
Regurgitation: A Systematic Review. JACC Cardiovasc Interv. 
2016; 9(22): 2308–2317, doi: 10.1016/j.jcin.2016.08.049, indexed 
in Pubmed: 28026742.
46. Dumesnil J, Pibarot P, Carabello B. Paradoxical low flow and/or 
low gradient severe aortic stenosis despite preserved left ventricu-
lar ejection fraction: implications for diagnosis and treatment. 
Eur Heart J. 2010; 31(3): 281–289, doi: 10.1093/eurheartj/ehp361.
47. Tribouilloy C, Rusinaru D, Maréchaux S, et al. Low-gradient, 
low-flow severe aortic stenosis with preserved left ventricular 
ejection fraction: characteristics, outcome, and implications for 
surgery. J Am Coll Cardiol. 2015; 65(1): 55–66, doi: 10.1016/j.
jacc.2014.09.080, indexed in Pubmed:25572511.
48. Lauten A, Figulla HR, Möllmann H, et al. TAVI for low-flow, 
low-gradient severe aortic stenosis with preserved or reduced 
ejection fraction: a subgroup analysis from the German Aortic 
Valve Registry (GARY). EuroIntervention. 2014; 10(7): 850–859, 
doi: 10.4244/EIJV10I7A145, indexed in Pubmed:25415152.
49. Kappetein A, Head S, Généreux P, et al. Updated standardized 
endpoint definitions for transcatheter aortic valve implantation: 
the Valve Academic Research Consortium-2 consensus docu-
ment†. Eur Heart J. 2012; 33(19): 2403–2418, doi: 10.1093/eu-
rheartj/ehs255.
50. Makkar R, Fontana G, Jilaihawi H, et al. Possible Subclinical 
Leaflet Thrombosis in Bioprosthetic Aortic Valves. New England 
Journal of Medicine. 2015; 373(21): 2015–2024, doi: 10.1056/nej-
moa1509233, indexed in Pubmed: 26436963.
51. Arsalan M, Walther T. Durability of prostheses for transcatheter 
aortic valve implantation. Nat Rev Cardiol. 2016; 13(6): 360–367, 
doi:10.1038/nrcardio.2016.43, indexed in Pubmed: 27053461.
52. Mylotte D, Andalib A, Thériault-Lauzier P, et al. Transcath-
eter heart valve failure: a systematic review. Eur Heart J. 2015; 
36(21): 1306–1327, doi:10.1093/eurheartj/ehu388, indexed in 
Pubmed: 25265974.
53. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guide-
line for the Management of Patients With Valvular Heart Disease: 
A Report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation. 2014; 
129(23): e521–e643, doi:10.1161/cir.0000000000000031, indexed 
in Pubmed: 24589853.
54. Osnabrugge RL, Speir AM, Head SJ, et al. Performance of EuroS-
CORE II in a large US database: implications for transcatheter 
aortic valve implantation. Eur J Cardiothorac Surg. 2014; 46(3): 
400–8; discussion 408, doi: 10.1093/ejcts/ezu033, indexed in 
Pubmed: 24574449.
55. Schoenenberger AW, Stortecky S, Neumann S, et al. Predictors 
of functional decline in elderly patients undergoing trans-
catheter aortic valve implantation (TAVI). Eur Heart J. 2013; 
34(9): 684–692, doi:  10.1093/eurheartj/ehs304, indexed in 
Pubmed: 23008508.
56. Tsang W, Bateman MG, Weinert L, et al. Accuracy of aortic annu-
lar measurements obtained from three-dimensional echocardiog-
raphy, CT and MRI: human in vitro and in vivo studies. Heart. 
2012; 98(15): 1146–1152, doi: 10.1136/heartjnl-2012-302074, 
indexed in Pubmed: 22773684.
57. Kleczyński P, Zasada W, Bagieński M, et al. Paravalvular leak 
after transcatheter aortic valve implantation (TAVI): Short-term 
results. Data from Polish national POL-TAVI registry. Cardiol J. 
2016; 23(2): 163–168, doi: 10.5603/CJ.a2015.0071, indexed in 
Pubmed: 26503080.
58. Willson AB, Webb JG, Labounty TM, et al. 3-dimensional aortic 
annular assessment by multidetector computed tomography 
predicts moderate or severe paravalvular regurgitation after 
transcatheter aortic valve replacement: a multicenter retro-
spective analysis. J Am Coll Cardiol. 2012; 59(14): 1287–1294, 
doi: 10.1016/j.jacc.2011.12.015, indexed in Pubmed: 22365423.
59. Spagnolo P, Giglio M, Di Marco D, et al. Feasibility of ultra-low 
contrast 64-slice computed tomography angiography before trans-
catheter aortic valve implantation: a real-world experience. Eur 
Heart J Cardiovasc Imaging. 2016; 17(1): 24–33, doi: 10.1093/ehj-
ci/jev175, indexed in Pubmed: 26160397.
60. Seiffert M, Fujita B, Avanesov M, et al. Device landing zone cal-
cification and its impact on residual regurgitation after transcath-
eter aortic valve implantation with different devices. Eur Heart 
J Cardiovasc Imaging. 2016; 17(5): 576–584, doi: 10.1093/ehj-
ci/jev174, indexed in Pubmed: 26160399.
61. Koos R, Mahnken AH, Dohmen G, et al. Association of aortic 
valve calcification severity with the degree of aortic regurgitation 
after transcatheter aortic valve implantation. Int J Cardiol. 2011; 
150(2): 142–145, doi: 10.1016/j.ijcard.2010.03.004, indexed in 
Pubmed: 20350770.
62. Lund O, Nielsen TT, Pilegaard HK, et al. The influence of coro-
nary artery disease and bypass grafting on early and late survival 
after valve replacement for aortic stenosis. J Thorac Cardiovasc 
Surg. 1990; 100(3): 327–337.
63. Thalji NM, Suri RM, Daly RC, et al. The prognostic impact of 
concomitant coronary artery bypass grafting during aortic valve 
www.kardiologiapolska.pl
Transcatheter aortic valve implantation
959
surgery: implications for revascularization in the transcatheter era. 
J Thorac Cardiovasc Surg. 2015; 149(2): 451–460, doi: 10.1016/j.
jtcvs.2014.08.073, indexed in Pubmed:25308117.
64. Chieffo A, Buchanan GL, Van Mieghem NM, et al. Transcatheter 
aortic valve implantation with the Edwards SAPIEN versus the 
Medtronic CoreValve Revalving system devices: a multicenter 
collaborative study: the PRAGMATIC Plus Initiative (Pooled-Rot-
terdAm-Milano-Toulouse In Collaboration). J Am Coll Cardiol. 
2013; 61(8): 830–836, doi: 10.1016/j.jacc.2012.11.050, indexed 
in Pubmed: 23333140.
65. Abdel-Wahab M, Mehilli J, Frerker C, et al. CHOICE investiga-
tors. Comparison of balloon-expandable vs self-expandable 
valves in patients undergoing transcatheter aortic valve replace-
ment: the CHOICE randomized clinical trial. JAMA. 2014; 
311(15): 1503–1514, doi: 10.1001/jama.2014.3316, indexed in 
Pubmed: 24682026.
66. Abdel-Wahab M, Mostafa AE, Geist V, et al. Comparison of out-
comes in patients having isolated transcatheter aortic valve implan-
tation versus combined with preprocedural percutaneous coronary 
intervention. Am J Cardiol. 2012; 109(4): 581–586, doi: 10.1016/j.
amjcard.2011.09.053, indexed in Pubmed: 22133754.
67. Pasic M, Dreysse S, Unbehaun A, et al. Combined elective percu-
taneous coronary intervention and transapical transcatheter aortic 
valve implantation. Interact Cardiovasc Thorac Surg. 2012; 14(4): 
463–468, doi: 10.1093/icvts/ivr144, indexed in Pubmed: 22232234.
68. Gasparetto V, Fraccaro C, Tarantini G, et al. Safety and effective-
ness of a selective strategy for coronary artery revascularization 
before transcatheter aortic valve implantation. Catheter Cardiovasc 
Interv. 2013; 81(2): 376–383, doi: 10.1002/ccd.24434, indexed in 
Pubmed: 22461314.
69. Abramowitz Y, Banai S, Katz G, et al. Comparison of early and late 
outcomes of TAVI alone compared to TAVI plus PCI in aortic ste-
nosis patients with and without coronary artery disease. Catheter 
Cardiovasc Interv. 2014; 83(4): 649–654, doi: 10.1002/ccd.25233, 
indexed in Pubmed: 24532332.
70. Griese DP, Reents W, Tóth A, et al. Concomitant coronary in-
tervention is associated with poorer early and late clinical out-
comes in selected elderly patients receiving transcatheter aortic 
valve implantation. Eur J Cardiothorac Surg. 2014; 46(1): e1–e7, 
doi: 10.1093/ejcts/ezu187, indexed in Pubmed:24819362.
71. Danson E, Hansen P, Sen S, et al. Assessment, treatment, and 
prognostic implications of CAD in patients undergoing TAVI. Nat 
Rev Cardiol. 2016; 13(5): 276–285, doi: 10.1038/nrcardio.2016.9, 
indexed in Pubmed: 26864912.
72. Ramee S, Anwaruddin S, Kumar G, et al. Aortic Stenosis AUC Writ-
ing Group, Interventional Section of the Leadership Council of the 
American College of Cardiology. The Rationale for Performance of 
Coronary Angiography and Stenting Before Transcatheter Aortic 
Valve Replacement: From the Interventional Section Leadership 
Council of the American College of Cardiology. JACC Cardiovasc 
Interv. 2016; 9(23): 2371–2375, doi:10.1016/j.jcin.2016.09.024, 
indexed in Pubmed: 27931592.
73. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus 
surgical aortic valve replacement in patients with severe aortic 
stenosis at low and intermediate risk: systematic review and 
meta-analysis. BMJ. 2016; 354: i5130, doi: 10.1136/bmj.i5130, 
indexed in Pubmed: 27683246.
74. Spitzer SG, Wilbring M, Alexiou K, et al. Surgical cut-down 
or percutaneous access-which is best for less vascular access 
complications in transfemoral TAVI? Catheter Cardiovasc In-
terv. 2016; 88(2): E52–E58, doi: 10.1002/ccd.26361, indexed in 
Pubmed: 26708225.
75. Ando T, Briasoulis A, Holmes AA, et al. Percutaneous versus 
surgical cut-down access in transfemoral transcatheter aortic 
valve replacement: A meta-analysis. J Card Surg. 2016; 31(12): 
710–717, doi: 10.1111/jocs.12842, indexed in Pubmed: 27699842.
76. Kochman J, Rymuza B, Huczek Z, et al. Incidence, Predic-
tors and Impact of Severe Periprocedural Bleeding According 
to VARC-2 Criteria on 1-Year Clinical Outcomes in Patients 
After Transcatheter Aortic Valve Implantation. Int Heart J. 
2016; 57(1): 35–40, doi: 10.1536/ihj.15-195, indexed in Pubmed:  
26673439.
77. Jagielak D, Bramlage P, Pawlaczyk R, et al. Transaortic 
transcatheter aortic valve implantation: Results of the Polish 
arm of the ROUTE registry. Cardiol J. 2015; 22(6): 651–656, 
doi: 10.5603/CJ.a2015.0046, indexed in Pubmed: 26202653.
78. Kochman J, Kołtowski L, Huczek Z, et al. Direct transcatheter 
aortic valve implantation - one-year outcome of a case control 
study. Postepy Kardiol Interwencyjnej. 2014; 10(4): 250–257, 
doi: 10.5114/pwki.2014.46766, indexed in Pubmed: 25489318.
79. Puls M, Sobisiak B, Bleckmann A, et al. Impact of frailty on 
short- and long-term morbidity and mortality after transcatheter 
aortic valve implantation: risk assessment by Katz Index of ac-
tivities of daily living. EuroIntervention. 2014; 10(5): 609–619, 
doi: 10.4244/EIJY14M08_03, indexed in Pubmed:25136880.
80. Green P, Cohen DJ, Généreux P, et al. Relation between six-min-
ute walk test performance and outcomes after transcatheter aortic 
valve implantation (from the PARTNER trial). Am J Cardiol. 2013; 
112(5): 700–706, doi: 10.1016/j.amjcard.2013.04.046, indexed in 
Pubmed: 23725996.
81. Mok M, Nombela-Franco L, Dumont E, et al. Chronic obstructive 
pulmonary disease in patients undergoing transcatheter aortic 
valve implantation: insights on clinical outcomes, prognostic 
markers, and functional status changes. JACC Cardiovasc Interv. 
2013; 6(10): 1072–1084, doi:10.1016/j.jcin.2013.06.008, indexed 
in Pubmed: 24156967.
82. Wilson CM, Kostsuca SR, Boura JA. Utilization of a 5-Meter Walk 
Test in Evaluating Self-selected Gait Speed during Preoperative 
Screening of Patients Scheduled for Cardiac Surgery. Cardiopulm 
Phys Ther J. 2013; 24(3): 36–43.
83. Asgar A, Lauck S, Ko D, et al. Quality of Care for Transcatheter 
Aortic Valve Implantation: Development of Canadian Cardiovas-
cular Society Quality Indicators. Canadian Journal of Cardiology. 
2016; 32(8): 1038.e1–1038.e4, doi: 10.1016/j.cjca.2015.11.008.
84. Stańska A, Jagielak D, Brzeziński M, et al. Improvement of 
quality of life following transcatheter aortic valve implanta-
tion in the elderly: a multi-centre study based on the Pol-
ish national TAVI registry. Kardiol Pol. 2017; 75(1): 13–20, 
doi: 10.5603/KP.a2016.0164, indexed in Pubmed: 27878802.
85. Iung B, Laouénan C, Himbert D, et al. FRANCE 2 Investigators. Pre-
dictive factors of early mortality after transcatheter aortic valve im-
plantation: individual risk assessment using a simple score. Heart. 
2014; 100(13): 1016–1023, doi: 10.1136/heartjnl-2013-305314, 
indexed in Pubmed: 24740804.
86. Arnold SV, Reynolds MR, Lei Y, et al. PARTNER Investiga-
tors. Predictors of poor outcomes after transcatheter aortic valve 
replacement: results from the PARTNER (Placement of Aortic 
Transcatheter Valve) trial. Circulation. 2014; 129(25): 2682–2690, 
doi: 10.1161/CIRCULATIONAHA.113.007477, indexed in Pub-
med: 24958751.
87. Seiffert M, Sinning JM, Meyer A, et al. Development of a risk 
score for outcome after transcatheter aortic valve implantation. 
Clin Res Cardiol. 2014; 103(8): 631–640, doi: 10.1007/s00392-
014-0692-4, indexed in Pubmed: 24643728.
88. Puri R, Iung B, Cohen DJ, et al. TAVI or No TAVI: identifying 
patients unlikely to benefit from transcatheter aortic valve im-
plantation. Eur Heart J. 2016; 37(28): 2217–2225, doi: 10.1093/eu-
rheartj/ehv756, indexed in Pubmed: 26819226.
89. Szymański P, Hryniewiecki T, Dąbrowski M, et al. Mitral and aor-
tic regurgitation following transcatheter aortic valve replacement. 
Heart. 2016; 102(9): 701–706, doi: 10.1136/heartjnl-2015-308842, 
indexed in Pubmed: 26908096.
www.kardiologiapolska.pl
Radosław Parma et al.
960
90. Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on 
the Management of Valvular Heart Disease of the European 
Society of Cardiology (ESC) and the European Association for 
Cardio-Thoracic Surgery (EACTS), ESC Committee for Practice 
Guidelines (CPG), Joint Task Force on the Management of Val-
vular Heart Disease of the European Society of Cardiology (ESC), 
European Association for Cardio-Thoracic Surgery (EACTS), Joint 
Task Force on the Management of Valvular Heart Disease of the 
European Society of Cardiology (ESC), European Association for 
Cardio-Thoracic Surgery (EACTS). Guidelines on the manage-
ment of valvular heart disease (version 2012). Eur Heart J. 2012; 
33(19): 2451–2496, doi:10.1093/eurheartj/ehs109, indexed in 
Pubmed: 22922415.
91. Kapadia SR, Tuzcu EM, Makkar RR, et al. Long-term outcomes 
of inoperable patients with aortic stenosis randomly assigned 
to transcatheter aortic valve replacement or standard therapy. 
Circulation. 2014; 130(17): 1483–1492, doi: 10.1161/CIRCULA-
TIONAHA.114.009834, indexed in Pubmed:25205802.
92. Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve re-
placement for degenerative bioprosthetic surgical valves: results 
from the global valve-in-valve registry. Circulation. 2012; 126(19): 
2335–2344, doi: 10.1161/CIRCULATIONAHA.112.104505, in-
dexed in Pubmed: 23052028.
93. Webb JG, Dvir D. Transcatheter aortic valve replacement for 
bioprosthetic aortic valve failure: the valve-in-valve procedure. 
Circulation. 2013; 127(25): 2542–2550, doi: 10.1161/CIRCULA-
TIONAHA.113.000631, indexed in Pubmed: 23797741.
94. Gąsior T, Huczek Z, Jagielak D, et al. Aortic valve-in-valve 
procedures for treatment of failing surgically implanted bio-
prosthesis. Cor et Vasa. 2017; 59(1): e35–e41, doi: 10.1016/j.
crvasa.2017.01.010.
95. Nishimura RA, Otto CM, Bonow RO, et al. American College of 
Cardiology/American Heart Association Task Force on Practice 
Guidelines. 2014 AHA/ACC guideline for the management of 
patients with valvular heart disease: executive summary: a report 
of the American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 
63(22): 2438–2488, doi:10.1016/j.jacc.2014.02.537, indexed in 
Pubmed: 24603192.
96. Passeri JJ, Melnitchouk S, Palacios IF, et al. Continued expansion 
of the Heart Team concept. Future Cardiol. 2015; 11(2): 219–228, 
doi:10.2217/fca.15.2, indexed in Pubmed: 25760880.
97. Holmes DR, Mohr F, Hamm CW, et al. Venn diagrams in car-
diovascular disease: the Heart Team concept. Ann Thorac Surg. 
2013; 95(2): 389–391, doi:10.1016/j.athoracsur.2012.06.071, 
indexed in Pubmed: 23317683.
98. Boothroyd LJ, Spaziano M, Guertin JR, et al. Transcatheter aortic 
valve implantation: recommendations for practice based on 
a multidisciplinary review including cost-effectiveness and ethi-
cal and organizational issues. Can J Cardiol. 2013; 29(6): 718–726, 
doi: 10.1016/j.cjca.2012.09.002, indexed in Pubmed: 23218465.
99. Dill KE, George E, Abbara S, et al. ACR appropriateness criteria 
imaging for transcatheter aortic valve replacement. J Am Coll 
Radiol. 2013; 10(12): 957–965, doi: 10.1016/j.jacr.2013.09.002, 
indexed in Pubmed: 24183748.
100. Vahanian A, Alfieri O, Al-Attar N, et al. European Association 
of Cardio-Thoracic Surgery, European Society of Cardiology, 
European Association of Percutaneous Cardiovascular Interven-
tions. Transcatheter valve implantation for patients with aortic 
stenosis: a position statement from the European Association of 
Cardio-Thoracic Surgery (EACTS) and the European Society of 
Cardiology (ESC), in collaboration with the European Associa-
tion of Percutaneous Cardiovascular Interventions (EAPCI). Eur 
Heart J. 2008; 29(11): 1463–1470, doi: 10.1093/eurheartj/ehn183, 
indexed in Pubmed: 18474941.
101. Bax JJ, Delgado V, Bapat V, et al. Open issues in transcatheter 
aortic valve implantation. Part 2: procedural issues and outcomes 
after transcatheter aortic valve implantation. Eur Heart J. 2014; 
35(38): 2639–2654, doi: 10.1093/eurheartj/ehu257, indexed in 
Pubmed: 25062953.
102. Urena M, Rodés-Cabau J. Managing heart block after trans-
catheter aortic valve implantation: from monitoring to device 
selection and pacemaker indications. EuroIntervention. 2015; 
11 Suppl W: W101–W105, doi: 10.4244/EIJV11SWA30, indexed 
in Pubmed: 26384171.
103. Walther T, Hamm CW, Schuler G, et al. GARY Executive Board. 
Perioperative Results and Complications in 15,964 Transcath-
eter Aortic Valve Replacements: Prospective Data From the 
GARY Registry. J Am Coll Cardiol. 2015; 65(20): 2173–2180, 
doi: 10.1016/j.jacc.2015.03.034, indexed in Pubmed: 25787198.
104. Gilard M, Eltchaninoff H, Donzeau-Gouge P, et al. FRANCE 
2 Investigators. Late Outcomes of Transcatheter Aortic Valve 
Replacement in High-Risk Patients: The FRANCE-2 Registry. 
J Am Coll Cardiol. 2016; 68(15): 1637–1647, doi:  10.1016/j.
jacc.2016.07.747, indexed in Pubmed: 27712776.
105. Grover F, Vemulapalli S, Carroll J, et al. 2016 Annual Report of 
The Society of Thoracic Surgeons/American College of Cardiol-
ogy Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 
2017; 69(10): 1215–1230, doi: 10.1016/j.athoracsur.2016.12.001, 
indexed in Pubmed: 27955994.
106. Siontis GCM, Jüni P, Pilgrim T, et al. Predictors of permanent 
pacemaker implantation in patients with severe aortic stenosis 
undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014; 
64(2): 129–140, doi:  10.1016/j.jacc.2014.04.033, indexed in 
Pubmed: 25011716.
107. Wilczek K, Reguła R, Bujak K, et al. Conduction disturbances 
after transcatheter aortic valve implantation procedures - pre-
dictors and management. Postepy Kardiol Interwencyjnej. 
2016; 12(3): 203–211, doi: 10.5114/aic.2016.61640, indexed in 
Pubmed: 27625682.
108. Van Der Boon RM, Nuis RJ, Van Mieghem NM, et al. New con-
duction abnormalities after TAVI--frequency and causes. Nat 
Rev Cardiol. 2012; 9(8): 454–463, doi: 10.1038/nrcardio.2012.58, 
indexed in Pubmed: 22547171.
109. Urena M, Hayek S, Cheema AN, et al. Arrhythmia burden in 
elderly patients with severe aortic stenosis as determined by 
continuous electrocardiographic recording: toward a better 
understanding of arrhythmic events after transcatheter aor-
tic valve replacement. Circulation. 2015; 131(5): 469–477, 
doi:  10.1161/CIRCULATIONAHA.114.011929, indexed in 
Pubmed: 25466975.
110. Brignole M, Auricchio A, Baron-Esquivias G, et al. European 
Society of Cardiology (ESC), European Heart Rhythm Associa-
tion (EHRA). 2013 ESC guidelines on cardiac pacing and cardiac 
resynchronization therapy: the task force on cardiac pacing and 
resynchronization therapy of the European Society of Cardiol-
ogy (ESC). Developed in collaboration with the European Heart 
Rhythm Association (EHRA). Europace. 2013; 15(8): 1070–1118, 
doi:10.1093/europace/eut206, indexed in Pubmed: 23801827.
111. Nazif TM, Dizon JM, Hahn RT, et al. PARTNER Publications Of-
fice. Predictors and clinical outcomes of permanent pacemaker 
implantation after transcatheter aortic valve replacement: the 
PARTNER (Placement of AoRtic TraNscathetER Valves) trial 
and registry. JACC Cardiovasc Interv. 2015; 8(1 Pt A): 60–69, 
doi: 10.1016/j.jcin.2014.07.022, indexed in Pubmed: 25616819.
112. Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death 
in patients undergoing transcatheter aortic valve replacement: 
incidence and predictors of advanced heart failure and sud-
den cardiac death. J Am Coll Cardiol. 2015; 65(5): 437–448, 
doi: 10.1016/j.jacc.2014.11.027, indexed in Pubmed:25660921.
113. Urena M, Webb JG, Cheema A, et al. Impact of new-onset 
persistent left bundle branch block on late clinical outcomes 
in patients undergoing transcatheter aortic valve implantation 
with a balloon-expandable valve. JACC Cardiovasc Interv. 
www.kardiologiapolska.pl
Transcatheter aortic valve implantation
961
2014; 7(2): 128–136, doi: 10.1016/j.jcin.2013.08.015, indexed in 
Pubmed: 24440024.
114. Lefèvre T, Kappetein AP, Wolner E, et al. One year follow-up 
of the multi-centre European PARTNER transcatheter heart 
valve study. Eur Heart J. 2011; 32(2): 148–157, doi: 10.1093/eu-
rheartj/ehq427, indexed in Pubmed: 21075775.
115. Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and 
clinical outcomes of transcatheter heart valve thrombosis. Circ 
Cardiovasc Interv. 2015; 8(4), doi:  10.1161/CIRCINTERVEN-
TIONS.114.001779, indexed in Pubmed: 25873727.
116. Hansson NC, Grove EL, Andersen HR, et al. Transcatheter Aortic 
Valve Thrombosis: Incidence, Predisposing Factors, and Clini-
cal Implications. J Am Coll Cardiol. 2016; 68(19): 2059–2069, 
doi: 10.1016/j.jacc.2016.08.010, indexed in Pubmed: 27580689.
117. Dangas GD, Weitz JI, Giustino G, et al. Prosthetic Heart Valve 
Thrombosis. J Am Coll Cardiol. 2016; 68(24): 2670–2689, 
doi: 10.1016/j.jacc.2016.09.958, indexed in Pubmed: 27978952.
118. Czerwińska-Jelonkiewicz K, Zembala M, Dąbrowski M, et al. 
Can TAVI patients receive aspirin monotherapy as patients 
after surgical aortic bioprosthesis implantation? Data from the 
Polish Registry - POL-TAVI. Int J Cardiol. 2017; 227: 305–311, 
doi: 10.1016/j.ijcard.2016.11.095, indexed in Pubmed: 27843052.
119. Huczek Z, Kochman J, Grygier M, et al. Pre-procedural dual 
antiplatelet therapy and bleeding events following transcatheter 
aortic valve implantation (TAVI). Thromb Res. 2015; 136(1): 
112–117, doi: 10.1016/j.thromres.2015.05.004, indexed in Pub-
med: 26004748.
120. Kuck KH, Eggebrecht H, Figulla HR, et al. Qualitätskriterien zur 
Durchführung der transvaskulären Aortenklappenimplantation 
(TAVI). Der Kardiologe. 2014; 9(1): 11–26, doi: 10.1007/s12181-
014-0622-8.
121. Raval A, Cigarroa J, Chung M, et al. Management of Patients on 
Non–Vitamin K Antagonist Oral Anticoagulants in the Acute 
Care and Periprocedural Setting: A Scientific Statement From 
the American Heart Association. Circulation. 2017; 135(10): 
e604–e633, doi: 10.1161/cir.0000000000000477.
122. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines 
for the management of atrial fibrillation developed in col-
laboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962, 
doi: 10.1093/eurheartj/ehw210, indexed in Pubmed: 27567408.
123. Heidbuchel H, Verhamme P, Alings M, et al. Advisors:. Updated 
European Heart Rhythm Association practical guide on the use 
of non-vitamin-K antagonist anticoagulants in patients with 
non-valvular atrial fibrillation: Executive summary. Eur Heart J. 
2016 [Epub ahead of print], doi:10.1093/eurheartj/ehw058, in-
dexed in Pubmed: 27282612.
124. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin Versus As-
pirin Plus Clopidogrel as Antithrombotic Treatment Following 
Transcatheter Aortic Valve Replacement With a Balloon-Ex-
pandable Valve: The ARTE (Aspirin Versus Aspirin + Clopi-
dogrel Following  Transcatheter Aortic Valve Implantation) 
Randomized  Clinical  Trial. JACC Cardiovasc Interv. 2017; 
10(13): 1357–1365, doi: 10.1016/j.jcin.2017.04.014, indexed in 
Pubmed: 28527771.
125. Habib G, Lancellotti P, Antunes MJ, et al. Document Review-
ers. 2015 ESC Guidelines for the management of infective 
endocarditis: The Task Force for the Management of Infective En-
docarditis of the European Society of Cardiology (ESC). Endorsed 
by: European Association for Cardio-Thoracic Surgery (EACTS), 
the European Association of Nuclear Medicine (EANM). Eur 
Heart J. 2015; 36(44): 3075–3128, doi: 10.1093/eurheartj/ehv319, 
indexed in Pubmed: 26320109.
126. Stokłosa P, Szymański P, Dąbrowski M, et al. The impact of trans-
catheter aortic valve implantation on left ventricular performance 
and wall thickness - single-centre experience. Postepy Kardiol In-
terwencyjnej. 2015; 11(1): 37–43, doi: 10.5114/pwki.2015.49183, 
indexed in Pubmed: 25848369.
127. Strom JB, Wimmer NJ, Wasfy JH, et al. Association between 
operator procedure volume and patient outcomes in per-
cutaneous coronary intervention: a systematic review and 
meta-analysis. Circ Cardiovasc Qual Outcomes. 2014; 7(4): 
560–566, doi: 10.1161/CIRCOUTCOMES.114.000884, indexed 
in Pubmed: 24939939.
128. Malenka D, McGrath P, Wennberg D, et al. The relationship 
between operator volume and outcomes after percutaneous coro-
nary interventions in high volume hospitals in 1994–199611A 
list of members of the Northern New England Cardiovascular 
Disease Study Group appears in Appendix B. J Am Coll Cardiol. 
1999; 34(5): 1471–1480, doi: 10.1016/s0735-1097(99)00393-9.
129. Tommaso CL, Bolman RM, Feldman T, et al. Multisociety (AATS, 
ACCF, SCAI, and STS) expert consensus statement: operator 
and institutional requirements for transcatheter valve repair 
and replacement, part 1: transcatheter aortic valve replacement. 
J Am Coll Cardiol. 2012; 59(22): 2028–2042, doi:  10.1016/j.
jacc.2012.02.016, indexed in Pubmed: 22387052.
130. Peterson ED, Coombs LP, DeLong ER, et al. Procedural volume as 
a marker of quality for CABG surgery. JAMA. 2004; 291(2): 195– 
–201, doi:10.1001/jama.291.2.195, indexed in Pubmed: 14722145.
131. Crawford FA, Anderson RP, Clark RE, et al. Volume require-
ments for cardiac surgery credentialing: a critical examination. 
The Ad Hoc Committee on Cardiac Surgery Credentialing of 
The Society of Thoracic Surgeons. Ann Thorac Surg. 1996; 
61(1): 12–16, doi: 10.1016/0003-4975(95)01017-3, indexed in 
Pubmed: 8561536.
132. Vassiliades TA, Block PC, Cohn LH, et al. Society of Thoracic 
Surgeons, American Association for Thoracic Surgery, Society for 
Cardiovascular Angiography and Interventions, American Col-
lege of Cardiology Foundation, American Heart Association. The 
clinical development of percutaneous heart valve technology: 
a position statement of the Society of Thoracic Surgeons (STS), 
the American Association for Thoracic Surgery (AATS), and the 
Society for Cardiovascular Angiography and Interventions (SCAI) 
Endorsed by the American College of Cardiology Foundation 
(ACCF) and the American Heart Association (AHA). J Am Coll 
Cardiol. 2005; 45(9): 1554–1560, doi: 10.1016/j.jacc.2004.12.024, 
indexed in Pubmed: 15862441.
133. Bagienski M, Kleczynski P, Dziewierz A, et al. Early- and 
mid-term outcomes after transcatheter aortic valve implanta-
tion. Data from a single-center registry. Postepy Kardiol Inter-
wencyjnej. 2016; 12(2): 122–127, doi: 10.5114/aic.2016.59362, 
indexed in Pubmed: 27279871.
134. Zembala-John J, Wilczek K, Tobota Z, et al. POL-TAVI - Polish 
Registry of Transcatheter Aortic Valve Implantation - simple tool, 
great value, rationale and design. Kardiochir Torakochirurgia Pol. 
2016; 13(4): 309–315, doi: 10.5114/kitp.2016.64870, indexed in 
Pubmed: 28096826.
Cite this article as: Parma R, Zembala MO, Dąbrowski M, et al. Transcatheter aortic valve implantation. Expert Consensus of the 
Association of Cardiovascular Interventions of the Polish Cardiac Society and the Polish Society of Cardio-Thoracic Surgeons, 
approved by the Board of the Polish Cardiac Society and National Consultants in Cardiology and Cardiac Surgery. Kardiol Pol. 2017; 
75(9): 937–964, doi: 10.5603/KP.2017.0175.
www.kardiologiapolska.pl
Radosław Parma et al.
962
APPENDIX 1. TAVI patient referral card
Date Referring Centre
PATIENT INFORMATION
Name Age
ID Weight
Address Height
Phone  BMI
CLINICAL INFORMATION
Diagnosis Symptoms Vertigo 
Syncope 
Angina CCS 
□ Dyspnoea NYHA 
 Vascular diseases Ischaemic heart disease 
□ Previous myocardial infarction 
Previous PCI 
□ Previous CABG 
Previous stroke 
Significant carotid artery disease 
Significant lower limb artery disease 
Cardiac arrhythmias Atrial fibrillation 
RBBB 
LBBB 
Pacemaker / ICD / CRT-D 
Structural heart diseases Heart failure 
Significant aortic valve regurgitation 
Significant mitral valve regurgitation 
Previous aortic valve replacement 
Previous mitral valve replacement 
Other comorbidities Renal failure 
Risk EuroSCORE II Chronic pulmonary disease 
STS Neurologic disease 
Katz ADL Cancer 
6-minute walk test Anaemia 
Qualified 
to TAVI
Yes
TAVI system
No Proposed 
date
TAVI Team signatures
Date
Route Transfemoral Other
Interventional Cardiologist Cardiac Surgeon
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APPENDIX 2. Checklist for TAVI procedure
PATIENT
Name Date of birth
Invasive Cardiologists Cardiac Surgeons
ANAESTHESIA
Anaesthesia Local  General 
Lines Arterial  Temporary RV pacing 
Venous 
TAVI SYSTEM
Access Transfemoral R / L  Access Min. artery diameter
Subclavian  Percutaneous  R L
Transcarotid  Surgical cutdown 
Direct aortic 
Transapical  Tortuosity Arterial  Aortic 
Transcaval  Calcification Arterial  Aortic 
Valve type Brand Aortic annulus Diameter
Area
Size Perimeter
VALVE IMPLANTATION
RV pacing required  Aortic valvuloplasty required 
Coronary ostia RCA ___ mm LCA ___ mm Preventive coronary artery wiring required 
Imaging C-arm projection TEE required 
PROCEDURAL RISK FACTORS 
CAD Incomplete revascularisation  PCI required 
Valve positioning Large, focal  calcium deposits (ÆPVL) 
Narrow coronary sinuses (Æcoronary artery occlusion) 
Narrow STJ (aortic root rupture) 
Significant mitral valve calcification (aortic root rupture, valve positioning) 
Heart morphology Bicuspid aortic valve 
Aortic bioprosthesis 
Native aortic valve regurgitation 
Right ventricle failure 
Significant tricuspid regurgitation 
Significant pulmonary hypertension 
LVEF < 40% 
Low left ventricular ejection volume 
Significant mitral regurgitation 
LA thrombi 
Renal function Creatinine / eGFR Type of contrast
Arrhythmias Atrial fibrillation  AV block         RBBB  LBBB 
Electrotherapy Pacemaker  ICD / CRT-D (re-programming before RV pacing)
Respiratory system Asthma / COPD 
Stature Obesity  Low height  Scoliosis 
DRUGS
Previous bleeding 
Antiplatelet drugs Aspirin  Clopidogrel  Ticagrelor         Other :
OAC Acenocoumarol  Warfarin  Rivaroxaban        Dabigatran 
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APPENDIX 3. TAVI procedure control chart
Patient Name TAVI System
Valve size
Age                                  Sex Access: transfemoral | other Side: R   |   L
STS                                 EuroSCORE II
Operators
PERSONNEL EQUIPMENT
 Briefing: description of possible procedural risks  TTE, TEE


acute care unit ready for patient admission  
cardiac surgeon, vascular surgeon, invasive  
cardiologists assisting or on alert
 Femoral artery occluders
 1–2 pigtail catheters
PROCEDURAL STRATEGY  Predilatation aortic balloon: size
 Sedation / general anaesthesia  Postdilatation aortic balloon: size
TEE on standby / continuous  Spare TAVI system
 Venous access for temporary pacing carotid,  
subclavian or femoral
 Rescue TAVI system (in valve dislocation): size
 Additional arterial line for blood pressure monitoring:  
radial or femoral
 Femoral sheaths (6, 10, 14, 18 F)
 C-arm projection (MSCT or 3D-TEE derived)  Guidewires: floppy J-curved and straight, teflon-coated
 Coronary artery guidewire protection?  Guidewires: stiff straight and preshaped
 Predilitation  Coronary guidewires
 RV pacing during valve implantation?  Guiding catheters: AL1, AL2, JR, pigtail, JL, JR, LIMA
PATIENT  Temporary pacing electrode
 Identity confirmed  Pacemaker (burst or > 200 bpm capable)
 Written informed consent  Pericardiocentesis set
 Blood type sampled and cross-matched  ECMO
 Blood bags prepared  Cardiac surgery / vascular surgery equipment
 Blood morphology  Coronary angiography and PCI equipment
 Creatinine, eGFR  Peripheral artery stenting equipment 
 Antiplatelet drugs, anticoagulation  Endografts
 INR, APTT  Cerebral protection systems
 LVEF
 Allergies
FINAL DECISIONS
 TAVI outcome assessment fluoroscopy: position, symmetry, aortography, pressure gradients, echocardiography, ECG
 Vascular access closure
 Temporary pacing lead removal
 Patient clinical status assessment
SUMMARY
 Procedural time  Decision on further intensive care, ambulation  
and pharmacotherapy Fluoroscopy time
 Radiation dose  Data backup: procedural reports, anaesthesia charts, cine, 
pressure recordings, echocardiography, ECG Contrast volume
Comments:
Nurse / Medical Technician signatures Operators signatures
